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Abstract
Background: In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas
where there is lack of evidence or low level of evidence. The St. Gallen Advanced Prostate
Cancer Consensus Conference (APCCC) 2017 addressed some of these topics.
Objective: To present the report of APCCC 2017.
Design, setting, and participants: Ten important areas of controversy in APC manage-
ment were identiﬁed: high-risk localised and locally advanced prostate cancer;
‘‘oligometastatic’’ prostate cancer; castration-naı¨ve and castration-resistant prostate
cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characteri-
sation of blood and tissue; genetic counselling/testing; side effects of systemic treat-
ment(s); global access to prostate cancer drugs. A panel of 60 international prostate
cancer experts developed the program and the consensus questions.
Outcome measurements and statistical analysis: The panel voted publicly but anony-
mously on 150 predeﬁned questions, which have been developed following a modiﬁed
Delphi process.
Results and limitations: Voting is based on panellist opinion, and thus is not based on a
standard literature review or meta-analysis. The outcomes of the voting had varying
degrees of support, as reﬂected in the wording of this article, as well as in the detailed
voting results recorded in Supplementary data.
Conclusions: The presented expert voting results can be used for support in areas of
management of men with APC where there is no high-level evidence, but individualised
treatment decisions should as always be based on all of the data available, including
disease extent and location, prior therapies regardless of type, host factors including
comorbidities, as well as patient preferences, current and emerging evidence, and
logistical and economic constraints. Inclusion of men with APC in clinical trials should
be strongly encouraged. Importantly, APCCC 2017 again identiﬁed important areas in
need of trials speciﬁcally designed to address them.
Patient summary: The second Advanced Prostate Cancer Consensus Conference APCCC
2017 did provide a forum for discussion and debates on current treatment options for
men with advanced prostate cancer. The aim of the conference is to bring the expertise of
world experts to care givers around the world who see less patients with prostate cancer.
The conference concluded with a discussion and voting of the expert panel on predeﬁned
consensus questions, targeting areas of primary clinical relevance. The results of these
expert opinion votes are embedded in the clinical context of current treatment of men
with advanced prostate cancer and provide a practical guide to clinicians to assist in the
discussions with men with prostate cancer as part of a shared and multidisciplinary
decision-making process.
# 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X4.0/).Please cite this article in press as: Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–341. Introduction
The panel for the 2017 Advanced Prostate Cancer Consensus
Conference (APCCC 2017) consisted of 60 multidisciplinary
cancer physicians and scientists from 21 countries selected
based on their academic track record and involvement in
clinical or translational research in the field advanced
prostate cancer (APC; Table 1).
For discussion, 10 controversial areas related to the
management of men with APC that were judged to be most
important for discussion were identified:
1. Management of high-risk localised and locally APC
2. ‘‘Oligometastatic’’ prostate cancer
3. Management of castration-sensitive/naı¨ve prostate
cancer
4. Management of castration-resistant prostate cancer
(CRPC)
5. Imaging in APC
6. Use of osteoclast-targeted therapy for skeletal related
events (SRE)/symptomatic skeletal events (SSE) pre-
vention for metastatic CRPC (mCRPC; not for osteopo-
rosis/bone loss)
7. Molecular characterisation
8. Genetic counselling/testing
9. Side effects of systemic treatment: prevention, man-
agement, and supportive care
10. Global access to prostate cancer drugs and treatment in
countries with limited resources.
The consensus development process followed the
procedures previously described (Supplementary data)
[1]. The conference was organised around state-of-the-art
lectures and presentations and debates by panellists who
reviewed and discussed the evidence relevant to the above
selected topics. On the last day of the conference,
150 previously agreed-upon questions were presented
with options for answers in a multiple-choice format. The
questions were voted on publicly but anonymously.
For all questions, unless stated otherwise, responses
were based on the idealised assumptions that all diagnostic
procedures and treatments (including expertise in their
interpretation and application) mentioned were readily
available; there were no treatment contraindications and
no option to include the patient in a clinical trial.
In addition, voting answers apply only to fit patients
without limiting comorbidities and for patients with
prostate adenocarcinoma (unless stated otherwise). When
metastases were mentioned, they were detected by bone
scintigraphy and/or cross-sectional imaging with computed
tomography (CT) and/or magnetic resonance imaging
(MRI), if not stated otherwise. Importantly, in an effort to
address questions from an evidence-based and clinical
utility perspective, panellists were specifically instructed
not to consider cost, reimbursement, and access as factors in
their deliberations, unless otherwise stated, although
Table 1 – Panel members by country and specialty
Name First name Speciality
Attard Gert Medical Oncology
Beer Tomasz M. Medical Oncology
Beltran Himisha Medical Oncology
Bossi Alberto Radiation Oncology,
nonvoting (absence
during voting)
Bristow Rob Radiation Oncology
Carver Brett Urology
Castellano Daniel Medical Oncology
Chung Byung Ha Urology
Clarke Noel Urology
Daugaard Gedske Medical Oncology
Davis Ian Medical Oncology
de Bono Johann Medical Oncology
Borges dos Reis Rodolfo Urology
Drake Charles G. Medical Oncology
Eeles Ros Clinical Oncology and Genetics
Efstathiou Eleni Medical Oncology
Evans Christopher Urology
Fanti Stefano Nuclear Medicine,
nonvoting member
Feng Felix Radiation Oncology
Fizazi Karim Medical Oncology
Frydenberg Mark Urology
Gleave Martin Urology
Gillessen Silke Medical Oncology
Halabi Susan Clinical Trials and Statistics,
nonvoting member
Heidenreich Axel Urology
Higano Celestia (Tia) Medical Oncology
James Nicolas Clinical Oncology
Kantoff Philip Medical Oncology
Kellokumpu-Lehtinen Pirkko-Liisa Clinical Oncology
Khauli Raja B. Urology
Kramer Gero Urology
Logothetis Chris Medical Oncology
Maluf Fernando Medical Oncology
Morgans Alicia K. Medical Oncology
and Epidemiology
Morris Michael Medical Oncology
Mottet Nicolas Urology
Murthy Vedang Radiation Oncology
Oh William Medical Oncology
Omlin Aurelius Medical Oncology,
nonvoting member
Ost Piet Radiation Oncology
Padhani Anwar Radiology, nonvoting member
Parker Chris Clinical Oncology
Pritchard Colin Pathology, nonvoting member
Roach Mack Radiation Oncology
Rubin Mark Pathology, nonvoting member
Ryan Charles Medical Oncology
Saad Fred Urology
Sartor Oliver Medical Oncology
Scher Howard Medical Oncology
Sella Avishay Medical Oncology
Shore Neal Urology
Smith Matthew Medical Oncology
Soule Howard Prostate Cancer Foundation,
nonvoting member
Sternberg Cora N. Medical Oncology
Suzuki Hiroyoshi Urology
Sweeney Christopher Medical Oncology
Sydes Matthew R Clinical Trials and Statistics,
nonvoting member
Tannock Ian Medical Oncology
Tombal Bertrand Urology
Valdagni Riccardo Radiation Oncology
Wiegel Thomas Radiation Oncology
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 3clearly these are critical factors in the decision making
for the physician and individual patient.Please cite this article in press as: Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the
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EURURO 7424 1–34The results are intended to serve only as a guide to
linicians to assist in the discussions with patients as part of
 shared and multidisciplinary decision-making process.
or the definitions used for APCCC 2017 please refer to
upplementary data.
The panel consisted of voting (52) and nonvoting
embers (8). The nonvoting members were panellists,
or example, radiologists, pathologists, and statisticians
ho are not involved in clinical management decision
aking, and one clinical expert who was not present during
he voting. The option ‘‘unqualified to answer’’ (short form
‘unqualified’’) should have been chosen if a panellist lacked
xperience for a specific question; the ‘‘abstain’’ option
hould have been chosen if a panellist felt unable to vote for
 best choice for any reason or had prohibitory conflicts of
nterest. The conference also included an explicit approach
o management of conflicts of interest (Supplementary
ata).
Detailed voting records for each of the questions brought
o the panel are provided in the Supplementary data. The
enominator was based on the number of panel members
ho voted on the particular question, excluding those who
oted ‘‘unqualified to answer.’’ In case of questions related
o a topic of a previous question where only a subset of the
anellists had voted for a specific answer option the votes of
anel members who voted ‘‘abstain’’ and ‘‘unqualified to
nswer’’ were excluded.
Consensus was declared if 75% of the panellists who did
ot vote for ‘‘unqualified’’ or abstained chose the same
ption [2]. Throughout, the percentage of voting panellists
ho gave a particular response are reported, the number of
oters, and the number of panellists for each answer are
rovided in the Supplementary data. All panellists have
ontributed to the designing of the questions, editing the
anuscript, and have approved the final document.
Importantly, this process was uniquely able to highlight
reas of disagreement and identified priorities for future
linical research, meaning areas where additional data
cquisition is warranted.
. High-risk localised and locally APC
he panellists noted that there is lack of precision in the use
f the term ‘‘high risk’’ in localised prostate cancer that is in
art influenced by a discipline specific perspective. The
ommonly used definitions of high-risk localised patients
y various societies plus the definitions used in the
TAMPEDE trial are summarised in Supplementary data
3]. High-risk localised patients have relatively good long-
erm outcomes [3,4]. For the APCCC 2017 conference, the
uropean Association of Urology (EAU) guideline definition
as used [5].
.1. Pathology in locally APC
athology reporting for radical prostatectomies (RP) should
dhere to the recently published American Joint Committee
Groups along with Gleason scores, the collapsing of pT2 to
one single group, and the use of elevated prostate-specific
antigen (PSA) to increase clinical staging. RP reports should
comment on tumour Gleason scores using the International
Society of Urological Pathology guidelines [7,8].
In men with positive lymph nodes, the total number of
nodes with metastases, the tumour volume within the
lymph node, and extracapsular nodal extension are poor
prognostic factors [9].
In tissue from patients who have previously been treated
with androgen deprivation therapy (ADT) and/or other
systemic treatment or radiation therapy (RT) no Gleason
score should be reported.
The panel unanimously agreed (100%) that apart from
morphology and tumour stage, the following factors should
be reported from a RP sample: (1) seminal vesicle
involvement, (2) extraprostatic extension, (3) positive
surgical margins (number, length and location, grade at
margin), (4) Gleason score, and (5) grade group. There was
also consensus that the following factors should be
reported: (1) extent of prostatic involvement (96%), (2)
number and anatomic region of resected lymph nodes and
number and location of involved lymph nodes (94%), (3)
tertiary Gleason grade (94%), and (4) micrometastases
versus macrometastases in involved lymph nodes (81%),
extranodal extension (81%), and metastatic deposits in
perinodal fat tissue (79%; Table 2).
Current guidelines (EAU, National Comprehensive Can-
cer Network [NCCN]) recommend performing extended
pelvic lymph node dissection for men with high-risk and
locally APC treated by RP particularly if the risk for lymph
node metastases based on available nomograms is estimat-
ed to be 5% despite the fact that there are no data from
randomised prospective trials supporting an improvement
in outcome with lymph node dissection [10–12]. The
impact of minimal template versus extended extent lymph
node dissection is not known and the pathological
processing and reporting of the dissected material is not
well defined.
There was a consensus (84%) that a lymph node
dissection should be performed in the majority of men
with cN0 cM0 high-risk prostate cancer undergoing RP
whereas 9% voted for a lymph node dissection in a minority
of selected patients and 5% did not vote for a lymph node
dissection.
Regarding the minimum number of lymph nodes to
constitute an adequate dissection in the majority of men
with cN0 cM0 high-risk prostate cancer 76% of the panellists
voted for a minimum of 11 lymph nodes (49% for 11–19
lymph nodes and 27% for  20 lymph nodes); 15% of the
panellists voted for five to 10 lymph nodes, 9% abstained.
Regarding the template of lymph node dissection in men
with high-risk and locally APC, there was a consensus that
the obturator region (98%), internal iliac region (90%), and
external iliac region (85%) should be dissected. Regarding
the presacral lymph nodes, 51% of the panellists voted
against and 46% in favour of dissection, similarly for
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X241
242n Cancer eighth edition cancer staging manual [6]. The
ew guidelines include the adoption of Prognostic GleasonPlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. common iliac lymph nodes 52% of the panellists voted
against and 45% in favour of dissection. There was at of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34Table 2 – Prostatectomy pathology reporting (as clinicians, which factors do you want to be reported from a prostatectomy specimen in men
with locally-advanced prostate cancer apart from morphology and tumour stage?)
Factor Yes, useful test for majority
of patients (inﬂuences your
management decision; %)
Only for minority
of selected
patients (%)
No (%) Abstain (%)
Seminal vesicle invasion 100 0 0 0
Extraprostatic extension 100 0 0 0
Positive surgical margins: number, length and
location as well as grade at margin
100 0 0 0
Gleason score and grade group 100 0 0 0
Extent of prostatic involvement 96 2 2 0
If lymphadenectomy is performed: number and
anatomic region of resected lymph nodes and
number and location of involved lymph nodes
94 6 0 0
Tertiary Gleason score 94 4 2 0
In any involved lymph nodes: micro- vs macrometastases 81 9 10 0
In any involved lymph nodes: extranodal extension 81 9 10 0
In any involved lymph nodes: metastatic deposits
in perinodal fat tissue
79 15 6 0
Cribriform growth pattern and intraductal tumour spread 73 14 13 0
Lymphovascular invasion 68 18 14 0
Intraductal carcinoma 67 21 12 0
Markers of inﬂammation (eg, inﬂammation within
prostate cancer tissue, tumour inﬁltrating lymphocytes)
23 24 53 0
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289consensus (95%) against routine dissection of para-aortic
lymph nodes (Table 3).
2.2. Adjuvant radiation therapy after RP
Adjuvant radiation therapy (ART) is largely considered as
the administration of external beam RT in the postoperative
phase in absence of objective evidence that disease has
recurred or persisted. In the case of prostate cancer this
would mean delivering RT when the PSA is ‘‘undetectable.’’
Interestingly, the definition of ‘‘undetectable’’ has varied
over the past 25 yr by nearly 100 fold from <0.3 ng/ml into
the pg/ml range more recently [13].
Three randomised controlled trials have demonstrated
that ART in case of unfavourable pathological features (eg,
pT3b, R1) after RP delays PSA recurrence free survival; in
one of these trials metastases-free survival and overall
survival (OS) were also improved. Interpretation of those
results is generally biased by the inclusion of men with
persistent disease evidenced by low but detectable PSA
levels [14–16]. Thus, in fact many of these patients treated
on the ART arm should be described as receiving early
salvage radiation therapy (SRT) [17,18].
Because several retrospective studies have shown that
SRT, offered at PSA recurrence, may be efficient and since290
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301
Table 3 – Lymph node (LN) dissection in localised prostate cancer
(which LN regions should be sampled [minimal requirement] in
men with cN0 cM0 high-risk prostate cancer?)
LN region Yes (%) No (%) Abstain (%)
Obturator 98 2 0
Internal iliac 90 10 0
External iliac 85 15 0
Presacral 46 51 3
Common iliac 45 52 3
Para-aortic 5 95 0
Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Euthis approach may save some men the application of ART,
many physicians defer treatment until there is evidence of
recurrent disease. Unfortunately there is no prospective
randomised trial comparing ‘‘pure’’ ART at undetectable PSA
levels as currently defined versus SRT at ‘‘appropriately’’
low PSA levels.
2.2.1. ART for high risk localised prostate cancer pN0
The topic of ART was addressed in men post-RP without
lymph node involvement on surgical pathology (pN0), with
undetectable postoperative PSA, and who have recovered
urinary continence.
There was no consensus on ART in high-risk localised
prostate cancer patients. Forty-eight percent of the
panellists voted for ART for any positive surgical margins,
whilst 27% of the panel voted for ART only in case of
multifocal or extensive margins. Twenty-one percent of the
panel did not vote for ART in this setting.
In the presence of seminal vesicle involvement alone 38%
of the panel voted for ART in the majority of patients, 32% of
the panel voted for ART only if combined with positive
surgical margins. Twenty-six percent of the panel did not
vote for ART at all in this setting.
Fifty-five percent of panellists did not vote for ART in the
case of Gleason 8–10 (Gleason Grade Group 4 or 5) as the
only adverse factor, 20% of the panel voted for ART in case of
Gleason 8–10 (Gleason Grade Group 4 or 5) alone for the
majority of patients, and 23% in a minority of selected
patients.
Regarding radiation field, 51% of the subset of panellists
who voted for ART voted for treatment of the whole pelvis
and prostatic bed, while 41% voted for treating only the
prostatic bed.
Thirty-six percent of the subset of panellists who voted
for ART voted for adding ADT in the majority of patients, 32%
in a minority of selected patients, and 32% did not vote for
the addition of ADT at all. From the subset of panellists whoof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34oted for addition of ADT to ART, 69% voted for this
ombined treatment in men with either pT stage 3b and/or
leason score 8 (Grade group 4–5); 28% voted for
ombined treatment in men with pT stage 3b alone
ndependent of Gleason score; and 3% voted for combined
reatment in men with Gleason 8–10 (Gleason Grade Group
 or 5) alone. Regarding the form of ADT 61% of the subset of
anellists voted for a luteinizing hormone-releasing hor-
one (LHRH) agonist/antagonist, 24% for combined ADT,
nd 15% for an androgen receptor antagonist monotherapy.
egarding duration of ADT, 39% of the subset of panellists
oted for 3–6 mo, 43% for 6–12 mo, and 18% for 18–36 mo of
DT.
.2.2. ART for pN1 prostate cancer
or men with prostate cancer and lymph node involvement,
ancer mortality rises significantly when >2 positive lymph
odes are present [19].
The question of ART in men with pN1 disease (assuming
dequate lymph node sampling, section 2.1) and no local
dverse factors (no pT3b, no R1) and undetectable
ostoperative PSA and who have recovered urinary conti-
ence was addressed by the consensus panel.
There was no consensus on ART in pN1 disease. Twenty-
ix percent of the panel voted for ART in men with pN1
isease in a majority of patients, 29% voted for ART in a
inority of selected patients, while 43% of the panel did not
ote for ART in this setting.
Regarding radiation field, 97% of the subset of panellists
ho voted for ART voted for the whole pelvis plus prostatic
ed as radiation field.
The subset of panellists who voted for ART also voted
n factors that influenced their decision to recommend
RT: 62% voted for taking both the number and location of
ositive lymph nodes into consideration when recommend-
ng ART, 33% based their decision only on the number
f involved lymph nodes, and 5% only on the location of
nvolved lymph nodes. Fifty percent of this subset of
anellists voted for ART in men with one or two positive
ymph nodes in the presence of intermediate- or high-
rade, nonorgan-confined disease and in those with three to
our lymph nodes irrespective of grade and T-stage, 17%
oted for ART in all patients, 15% voted for ART in patients
ith 2 positive lymph nodes independent of grade and
-stage, and 15% in patients with 4 positive lymph nodes
ndependent of grade and T-stage.
Of the panellists who voted for ART for pN1 disease, 100%
oted for adding ADT to ART. Regarding the duration of ADT
n this situation, 18–36 mo was voted for by 57% of these
anellists, 6–12 mo by 30%; 11% voted for 3–6 mo, while 2%
oted for life-long ADT.
.3. SRT
hile RP generally yields excellent results in patients
ith localised prostate cancer, the recurrence rates
fter RP for high-risk prostate cancer may rise as high as
0–80% [15]. In the case of recurrence, SRT is a treatment
ption [20].Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. The appropriate PSA level at which to initiate SRT is still
unclear. European guidelines recommend initiating SRT
before the post-RP PSA level exceeds 0.5 ng/ml, whilst NCCN
guidelines recommend SRT in patients with confirmed
increasing PSA [21,22].
Two multi-institutional retrospective studies showed an
improved freedom from biochemical progression and
distant metastases following very early SRT at a PSA
<0.2 ng/ml as opposed to patients in which SRT was
initiated at a PSA level of 0.2–0.5 ng/ml versus higher PSA
values [23,24]. Such analyses are confounded by lead-time
and length-time bias and the topic remains an area of
uncertainty.
According to the current EAU guidelines, the SRT dose
should be at least 66 Gy but the optimal dose may be
higher; the optimal dose and fractionation is unclear and is
being addressed in several ongoing trials.
Combining SRT with ADT may be an option, particularly
in men with high-risk disease. In the GETUG-AFU 16 trial,
the 5-yr freedom from biochemical progression was 80%
with SRT plus 6 mo of ADT versus 62% with SRT alone
[25]. In the RTOG 9601 trial, OS was improved with SRT plus
2 yr of high-dose bicalutamide (150 mg daily) compared
with SRT plus placebo but a significant proportion of
included men had PSA levels 0.7 ng/ml [26].
Regarding the confirmed PSA level at which to initiate
SRT, 44% of the panel voted for 0.2 ng/ml, whilst 38%
voted for 0.1 ng/ml, 10% voted for 0.5 ng/ml, and 4% for
<0.1 ng/ml.
The panel reached no consensus regarding a level of PSA
above which SRT would not be recommended. Twenty-five
percent of the panellists considered 2 ng/ml the maximum
value, 19% considered 1 ng/ml the maximum value, 11%
chose 0.5 ng/ml as a maximum value, and 19% of the panel
voted that there should be no maximal upper limit of PSA.
The subset of panellists who voted for SRT also voted on
the addition of ADT. Sixty-one percent voted for ADT in the
majority of men, 29% in a minority of selected patients, for
example, based on PSA level and PSA doubling-time, and
10% of these panellists did not vote for the addition of ADT.
Regarding the duration of ADT in combination with SRT,
34% of these panellists who opted for the addition of ADT
voted for 3–6 mo, 41% for 6–12 mo, and 25% for 18–36 mo of
ADT.
2.4. Discussion of high-risk localised and locally APC
The consensus questions focused on men undergoing RP
and the topics of ART and SRT. The choice of primary
treatment of high-risk and locally advanced prostate cancer
is also an area of controversy, but was not addressed at this
conference.
The votes of the panel showed a consensus on the
required information for pathology reporting in men
undergoing a RP.
There was a lack of consensus regarding the role of ART
and SRT reflecting the many uncertainties and multiple
unanswered questions in both topics. One of the reasons for
uncertainty is that the ART trials did not have an early SRTt of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34arm as a comparator and as such are not comparable to
current practice. Another weakness of these trials is the
relatively high PSA at which ‘‘adjuvant’’ RT was started,
again not comparable to current practice.
As with any adjuvant treatment, ART bears the risk of
overtreatment and can result in acute side effects as well as
deleterious effects on long-term functional outcome (eg,
potency, continence) but such potential risks must be
balanced against the potential benefits, namely improved
oncological outcomes [18,27,28].
The quest to define ‘‘unnecessary’’ RT and how to select
which patients really require ART and for which patients
SRT is appropriate is currently ongoing. Several well-
powered phase 3 trials (RADICALS, RAVES, and GETUG-17)
will provide evidence on which to base updated discussions.
In the meantime, regarding SRT, recent retrospective
studies suggest that initiating SRT at lower PSA values
(< 0.2 ng/ml) improves biochemical progression free
survival as compared with using the traditional recom-
mended confirmed value of 0.2 ng/ml and rising for
definition of biochemical relapse (BCR) [23,24]. These data
were reflected by the votes of the panel wherein a significant
proportion of panellists would initiate SRT below the PSA
threshold recommended by current guidelines.
The addition of ADT to RT as primary treatment of the
prostate is a well-established concept [29–33]. But the
addition, timing, and duration of ADT, specifically for ART
but also for SRT, are less well examined [26]. Accordingly,
there was no consensus regarding the role of adding ADT to
ART and SRT.
Prospectively validated prognostic and predictive mo-
lecular biomarkers are required that will improve the
performance of clinical and pathological features but this
can only be determined in the context of large phase
3 randomised trials with adequate long-term follow-up.
Additionally, the increasing use of next-generation imaging
methods in combination with more sensitive PSA assays
may also alter treatment approaches in the future.
3. Oligometastatic prostate cancer
3.1. Definition of oligometastatic prostate cancer
Hellman and Weichselbaum [34] proposed the term
‘‘oligometastases’’ in 1995 for defining a disease stage with
a limited number of clinically detectable metastases.
The biological definition of oligometastatic prostate
cancer is open to interpretation as is the entire concept
that this is a prognostic and therapeutically distinct subset
of patients that falls somewhere in-between localised and
metastatic disease. No formal cut-off for ‘‘oligo’’ has been
defined in the literature [35]. Some definitions incorporate
both the site of metastases in addition to the number of
lesions to define the oligometastatic state [35,36]. Variables
to include in the description of men with oligometastatic
disease include: the distinction of synchronous versus
metachronous metastases, the number and site of lesions,
and whether the patient is castration-naı¨ve or castration-
resistant [36]. Of importance is also the imaging methodPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Euused to define oligometastatic disease. Newer imaging
techniques will detect more metastases in many patients
classified as ‘‘oligometastatic’’ by conventional imaging (CT
and bone scintigraphy). Many patients considered as M0 on
conventional imaging may turn out to have oligometastatic
disease especially when imaging is performed at lower PSA
levels than in the past.
The panel did not reach consensus on what constituted
the definition of oligometastatic disease. Sixty-one percent
of the panellists voted for a limited number of bone and/or
lymph nodes as a clinically meaningful definition of
oligometastatic prostate cancer that influences treatment
decisions (local ablative treatment of all lesions  systemic
therapy), 10% of the panellists voted for an oligometastatic
definition which includes only patients with a limited number
of lymph node metastases, 13% voted for patients with a
limited number of metastases at any location (including
visceral disease), and 10% of the panellists did not believe that
oligometastatic prostate cancer exists as a clinically mean-
ingful entity.
The subset of panellists who believed in the concept of
oligometastatic prostate cancer voted on the number of
lesions. Regarding the cut-off for the number of metastases
to consider a prostate cancer patient as oligometastatic 14%
voted for 2 metastases, 66% for 3 metastases, and 20% of
these panellists voted for 5 metastases as a cut-off. Of
these panellists believing in the oligometastatic concept,
52% voted for a biopsy (if feasible) of an oligometastatic
lesion for diagnostic purposes in a minority of selected
patients, while 34% voted for biopsy in the majority of
patients and 14% of these panellists did not vote for a
biopsy.
3.2. Synchronous ‘‘oligometastatic’’ prostate cancer
This section addresses patients diagnosed with de novo
apparent oligometastatic disease in the castration-naı¨ve
state, that is, they present with synchronous oligometas-
tases and an untreated primary. In such patients, no
prospective randomised data are available to show a benefit
for ablative treatment all lesions including the primary—
either with or without systemic therapy.
For men who present with de novo oligometastatic
disease, a total of 25% of the panellists voted for lifelong ADT
 six cycles of docetaxel without local ablative treatment.
Eight percent of panellists voted for local ablative treatment of
all lesions including the primary (surgery or RT) without any
systemic treatment, 22% of panellists voted for local ablative
treatment with a short course (6–12 mo) of ADT  docetaxel,
31% of panellists voted for local ablative treatment and an
intermediate long course (24–36 mo) of ADT  docetaxel, 8%
of panellists voted for local ablative treatment and life-long
ADT  docetaxel.
Among the panellists who voted for local ablative
treatment plus ADT in men with de-novo oligometastatic
prostate cancer and an untreated primary, 28% voted for the
addition of docetaxel in the majority of patients, 39% voted
for the addition of docetaxel in a minority of selected
patients; 33% of these panellists did not vote for theof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34ddition of docetaxel in this situation. If they voted for
reatment of the primary tumour in this situation, 45%
oted for RT, 22% voted for surgery, and 31% voted for either
T or surgery.
.3. Metachronous oligometastatic castration-naı¨ve prostate
ancer
his section addresses men who present with recurrent
pparent oligometastatic prostate cancer in the castration-
aı¨ve state (CNPC); that is, they present with metachro-
ous metastases after local treatment of the primary. No
rospective randomised data are available to show a
enefit for radical ablative treatment of all lesions with or
ithout systemic therapy as compared with standard of
are (ADT  docetaxel) [37]. A meta-analysis of 20 small
tudies of local lymph node only recurrence after primary
reatment suggested that, despite a lack of high-level
vidence, ablative node-directed therapy may yield in good
hort-term oncologic outcomes and may defer the need for
ystemic treatment [38].
There was no consensus on treatment options. For
reatment of men with asymptomatic oligometastatic
ecurrent CNPC 32% of the panel voted for systemic therapy
ith lifelong ADT  docetaxel without local ablative therapy
f the metastases. Twelve percent voted for local ablative
herapy of the metastases without additional systemic
herapy, while 30% voted for local ablative therapy with a
hort course (6–12 mo) of ADT  docetaxel, 18% for local
blative therapy with a longer course (24–36 mo) of ADT 
ocetaxel, and 4% voted for local ablative therapy and lifelong
DT  docetaxel.
Among the panellists who voted for local ablative
reatment in men with oligometastatic recurrent CNPC
imited to lymph node metastases in the pelvis, 23% voted
or salvage lymph node dissection, 19% for salvage lymph
ode dissection plus RT to the pelvis (if no prior whole-
elvis RT), 16% of these panellists voted for focal RT, and 42%
or whole pelvis RT (if no prior whole-pelvis RT)  a boost to
he suspicious nodes.
.4. Rising PSA on ADT (mCRPC) and oligometastatic disease
his section addresses patients diagnosed with oligometa-
tatic disease progression in the castration resistant state.
o prospective randomised data are available demonstrat-
ng a benefit for local radical treatment of all lesions in
ddition to ADT, compared with standard of care, that is, the
ddition of a new systemic treatment to ADT.
Among the panellists who believed that oligometa-
tatic mCRPC is a meaningful entity there was no
onsensus on treatment options. Forty-four percent of
hese panellists voted for continuation of ADT and adding
dditional systemic therapy, 29% for local ablative
reatment of all lesions in combination with ongoing
DT and addition of systemic treatment, 25% for local
blative treatment of all lesions while continuing ADT,
nd 2% voted for local ablative treatment of all lesions and
he cessation of ADT.Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. 3.5. Discussion of oligometastatic prostate cancer
In addition to prostate cancer, the oligometastatic state is of
interest in a growing number of other cancer types, for
example, breast, renal cell, colorectal, gastric, and nonsmall
cell lung cancer. Like in prostate cancer, in these diseases
the majority of data are retrospective in nature and
therefore difficult to interpret. In some cases, treatment
of local disease appears to be associated with long-term
survival. Prospective trials are ongoing in several of these
entities.
The concept of oligometastases implies that a local
therapy directed at the primary cancer and/or metastases
might improve survival though there is no strong evidence
to support this. There was no consensus on treatment
options, but from the voting it seems that the enthusiasm
for the topic exceeds the evidence reported to date. The
available data are not prospective, are subject to selection
bias, and thus require validation in prospective randomised
controlled trials. Such trials should focus on OS as an
endpoint, since earlier endpoints such as progression-free
survival (PFS) or time to systemic therapy are not well
defined and their clinical importance is less clear. Distin-
guishing between synchronous and metachronous lesions,
and separating pelvic nodal relapse from M1 disease is also
likely to be important. Studies of patients with oligometa-
static disease are of increasing importance, since more
sensitive imaging techniques are anticipated to increase the
proportion of men with radiographically detected lesions.
At the very least, until randomised clinical trial data are
available, large collaborative national and international
registries of men treated for oligometastatic prostate cancer
should be initiated to prospectively collect data on
consecutively treated patients.
4. CNPC
There was inconsistent use in discussions of the terms
castration-naı¨ve or castration-sensitive, to designate pros-
tate cancer either not previously treated with ADT, or
cancers demonstrating ongoing sensitivity to ADT. The term
castration-naı¨ve (CNPC) is used in this manuscript for
simplicity to cover both clinical scenarios.
4.1. When to start ADT (post-RP W RT or postradical RT)
The optimal timing of initiation of ADT, duration, specific
ADT modality, and the indications for initiating ADT are not
well defined. For patients presenting with metastases with
impending complications and especially if symptomatic, an
initial short course of AR antagonist treatment to prevent
the unwanted clinical consequences of testosterone surge is
recommended when LHRH agonists are initiated.
For patients with BCR, the decision to initiate ADT will
likely depend upon several parameters including life
expectancy, time to PSA relapse after local therapy, PSA
kinetics, absolute PSA level, age, sexual function, baseline
fatigue, cardiovascular risk, and neurologic and cognitive
status. For patients with BCR without overt metastatict of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34disease, the decision to proceed with intermittent ADT
versus continuous ADT should also be considered.
In men with nonmetastatic disease and confirmed rising
PSA (postlocal therapy  SRT), 65% of the panellists voted for
the initiation of ADT only in a minority of selected men, for
example, in case of a PSA 4 ng/ml and rising with doubling
time less than 6 mo or a PSA 20 ng/ml (STAMPEDE inclusion
criteria). Twenty-one percent voted for starting ADT in the
majority of men irrespective of these factors and 12% voted for
starting ADT only after detection of metastases.
4.1.1. Monitoring of testosterone
Current data do not provide clarity regarding the optimal
level of testosterone suppression to be achieved in men
with advanced prostate cancer on ADT. The regulatory-
approved level of less than 50 ng/dl, per Food and Drug
Administration and European Medicines Agency, was based
upon the initial leuprolide registration trial and 50 ng/dl
was the lowest limit of detection of the radioimmunoassay
used at that time [39]. Ensuing trials have suggested that
reaching a testosterone level of 20 ng/dl may achieve a
delay in time toward the development of castration
resistance; however, this threshold, as well as the interval
at which to measure serum testosterone levels remains
uncertain [40].
In men with prostate cancer responding to ADT, 44% of
the panel voted for regular monitoring of testosterone levels
(apart from measuring testosterone at biochemical pro-
gression) and 34% of the panellists voted for measuring
testosterone in a minority of selected patients (eg, failure to
achieve PSA nadir < 0.2 ng/ml), 22% of the panel did not vote
for regular testosterone measurement in responding
patients.
Fifty-four percent of the panel voted for a testosterone
level <50 ng/dl (< 1.73 nmol/l) as appropriate for men
on ADT, 36% voted for a testosterone level <20 ng/dl
(< 0.69 nmol/l), while 10% abstained.
There was no consensus on the therapeutic approach to
men with rising PSA on a LHRH agonist whose testosterone
level is confirmed as being noncastrate (apart from ruling
out application errors and/or poor compliance). Despite the
lack of evidence, 36% of the panel voted for a change to a
LHRH antagonist, 26% for addition of a first-generation AR
antagonist, 20% for a change to an alternative LHRH agonist,
and 14% voted for orchiectomy.
4.2. Chemotherapy in castration-naı¨ve nonmetastatic prostate
cancer
There is some evidence to support combination treatment
as an upfront alternative to single-modality therapy for men
who present with high-risk localised prostate cancer. Such
approaches generally combine ADT with RT and docetaxel-
based chemotherapy. A total of three randomised trials in
such patients have been reported. The GETUG-12 trial
showed an improvement in failure-free survival (FFS) with
four cycles of docetaxel and estramustine plus ADT as
compared with ADT alone [41,42]. The second trial, RTOG
0521, so far only presented as an abstract, examined thePlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eucombination of six cycles of adjuvant docetaxel postradical
RT with ADT for 24 mo (NCT00288080). The STAMPEDE trial
allowed inclusion of high-risk localised as well as biochem-
ical recurrent and metastatic patients. The number of
events for definitive interpretation of survival of M0
patients in the docetaxel arm of STAMPEDE is too low
and no conclusions regarding the effect of addition of
docetaxel on OS in this trial can be drawn [43].
A meta-analysis reported a consistent effect on FFS for
chemo-hormonal therapy in the M0 subgroup treated with
ADT plus RT as opposed to ADT alone [44]. Data for OS are
not yet mature.
For men with N1 M0 CNPC, 71% of the panel did not vote
for the addition of docetaxel to ADT, 25% voted for it for a
minority of selected patients, and 4% for the majority of
patients.
For men with biochemical relapse only, there was a
consensus (90%) for not adding docetaxel to ADT.
4.3. CNPC M1 (metastatic)
Testosterone suppression alone has long been the standard
treatment for patients with metastatic prostate cancer
commencing systemic treatment [45]. Although the major-
ity of men with mCNPC experience a PSA decline with ADT,
the median FFS is approximately 1 yr, with a wide range
[46]. Subgroup analyses from recent clinical trials showed
that higher volume of metastases and presentation with de
novo metastatic disease are risk factors associated with a
shorter OS with ADT alone. Other purported poor prognostic
clinical factors include higher Gleason score, pain, and
elevated alkaline phosphatase [45,47,48].
Docetaxel given at the start of ADT was the first drug
shown to improve the OS of men with mCNPC in two large
trials [43,49]. The first phase 3 study of docetaxel in mCNPC,
GETUG 15, showed an improvement in PFS but not OS.
There is ongoing discussion on the definition of ‘‘high-
volume’’ disease and whether there is a definition that is
prognostically relevant or predictive of treatment benefit.
For a definition of high-volume disease, 74% of the
panellists voted for the definition, as used in CHAARTED
(visceral [lung or liver] and/or  4 bone metastases, at least
one beyond pelvis and vertebral column), either with
standard imaging (59%) or with any imaging (15%), 6% voted
for the high-volume definition developed by SWOG
(visceral [lung or liver] and/or any appendicular skeletal
involvement) and 6% voted for a simplified version of high-
volume of visceral and/or 4 bone lesions regardless of
distribution and imaging used. Forteen percent of the
panellists had the opinion that high-volume disease is not a
clinically meaningful entity.
For men with high-volume mCNPC, 68% of the panellists
voted for continuous ADT using a LHRH agonist (plus a short
course of first-generation AR antagonist to prevent testos-
terone surge) as their preferred hormone therapy, another
10% for starting with an LHRH antagonist (no flare-up
prevention needed) and switching to an LHRH agonist in the
course of treatment. Continuous LHRH antagonist treat-
ment was voted for by 6%, orchiectomy by 2%, andof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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Table 4 – Definition ‘‘unfit’’ for docetaxel
What are meaningful deﬁnitions ‘‘not being suitable
for docetaxel’’, apart from allergy to the substance
(‘‘docetaxel ineligible’’)?
Yes (%) Only in combination
with other factors (%)
No (%) Abstain (%)
Severe hepatic impairment (eg, ALT/AST > 5  ULN
and/or bilirubin > 3  ULN)
96 2 2 0
Neuropathy grade 2 82 18 0 0
Platelets <50  109/l and/or neutrophils <1.0  109/l 81 15 4 0
Frailty assessed by geriatric or other health status evaluation 69 29 2 0
Performance status 2 for reasons other than cancer 62 32 4 2
Moderate hepatic impairment (eg, ALT/AST > 3–5  ULN
and/or bilirubin > 1.5–3  ULN)
52 48 0 0
ALT = alanine transaminase; AST = aspartate transaminase; ULN = upper limit of normal.
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EURURO 7424 1–34ontinuous combined ADT by 14% of the panellists.
one of the panellists voted for any form of intermittent
DT or AR-antagonist monotherapy in the high-volume M1
etting.
Not all men are suitable for chemotherapy with
ocetaxel and the criteria rendering a patient ‘‘unsuitable’’
or docetaxel are not well defined.
The panel voted on factors they would consider
endering a man ‘‘unfit’’ for docetaxel.
There was a consensus for severe hepatic impairment
96%), neuropathy grade 2 (82%), and platelets <50  109/l
nd/or neutrophils <1.0  109/l (81%). For the other
roposed factors alone there was no consensus (Table 4).
In the original publication of the CHAARTED trial, the
ubgroup of men with high-volume disease showed a
linically significant survival benefit and the point estimate
or the low volume patients was the same in that
ublication, albeit with much wider confidence intervals
49]. No OS benefit has yet been demonstrated for early
ocetaxel use with longer-term follow-up in subgroup
nalyses performed in both the low-volume mCNPC cohorts
f the GETUG 15 (posthoc) or CHAARTED (prespecified)Table 5 – Chemo-hormonal therapy with docetaxel
Do you recommend docetaxel in addition
to ADT:
Yes, in the majority o
patients (%)
in men with de novo metastatic castration-naive
prostate cancer and high-volume disease as
deﬁned by CHAARTED (visceral metastases
and/or  4 bone lesions with  1 beyond
vertebral bodies and pelvis)?
96 
in men with de novo metastatic castration-naive
and low-volume disease as per CHAARTED?
29 
in men with metastatic castration-sensitive/naive
disease relapsing after prior treatment for
localised prostate cancer and with high-volume
disease as per CHAARTED?
74 
in men with metastatic castration-sensitive/naive
disease relapsing after prior treatment for
localised prostate cancer with low-volume bone
metastases as per CHAARTED criteria?
19 
in men with castration-sensitive/naive N1 M0
prostate cancer?
4 
in men with castration-sensitive/naive N0 M0
(nonmetastatic) prostate cancer with
biochemical relapse?
0 
ADT = androgen deprivation therapy.
Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. trials [49,50]. Further subgroup analyses for men with de
novo metastatic prostate cancer (majority of included
patients) versus men with relapse after local treatment
were presented but have not yet been published (European
Society for Medical Oncology 2016 and GU-ASCO 2017).
The large STAMPEDE trial included both M0 and M1
patients and no heterogeneity of treatment effect was
observed.
For men who are suitable for chemotherapy and
have de novo mCNPC and high-volume disease as defined
by CHAARTED, there was a consensus (96%) for addition
of docetaxel to ADT in the majority of patients, 4% voted
for docetaxel in a minority of these men. For the other
subgroups of mCNPC there was no consensus (Table 5).
There was consensus that men with biochemical relapse
(N0M0) should not receive docetaxel in addition to ADT.
If chemo-hormonal treatment is used in men with
mCNPC there was consensus (78%) that docetaxel should be
started within 3 mo of starting ADT and 20% of these
panellists voted for starting even within 2–4 wk. Within
4 mo was considered sufficient for another 18% of the
panellists.f In a minority of
selected patients (%)
No (%) Abstain (%) Unqualiﬁed
to answer (%)
4 0 0 0
65 9 0 0
24 2 0 0
54 25 2 0
25 71 0 0
10 90 0 0
t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34In the subset of panellists who voted for chemo-hormonal
therapy there was also consensus (96% of the panel) for the
3-weekly regimen of docetaxel with 75 mg/m2. Only 4% of
the panel voted for the use of the 2-weekly regimen with
50 mg/m2.
Docetaxel in the 3-weekly regimen does not bear a high
risk (>2 0%) of febrile neutropenia; however, according to
existing guidelines (NCCN, European Society for Medical
Oncology, American Society of Clinical Oncology [ASCO]),
primary granulocyte-colony stimulating factor prophylaxis
should be considered in men with risk factors namely prior
chemo- or RT, bone marrow involvement by tumour, renal
dysfunction (creatinine clearance < 50 ml/min), or age
>65 yr, and receiving full chemotherapy dose and intensity.
It is not uncommon that such risk factors are present in men
with APC. Of note, there is preclinical data suggesting that
myeloid-derived suppressor cells, which may play a role in
cancer progression can be influenced by granulocyte-colony
stimulating factor [51–53].
In the subset of panellists who voted for chemo-
hormonal therapy, 6% voted for white blood cell (WBC)
growth factors from start of therapy in the majority of
patients, 50% for a minority of selected patients. Forty-four
percent of these panellists did not vote for WBC growth
factors from start of therapy.
Regarding concomitant steroid dosing the CHAARTED
and GETUG-15 trials did not require daily steroids, whereas
STAMPEDE required prednisone (10 mg) daily.
In the subset of panellists who voted for chemo-
hormonal therapy, 58% voted for prescribing the 3-weekly
docetaxel regimen with no daily steroid in the chemo-
hormonal setting and 38% of the panellists with 10 mg
prednisone daily.
4.4. Local therapy in men with mCNPC
The current standard of care for patients presenting with de
novo metastatic prostate cancer is ADT with or without
docetaxel (section 4.2). Transurethral resection of the
prostate may be used to palliate local symptoms. The
rationale for potentially using a local ablative treatment
(external beam RT or RP) in these patients is based on
several considerations. Significant morbidity related to local
symptoms including pain, obstructive urinary symptoms,
and haematuria can occur in these men, either when the
cancer is diagnosed or when it progresses later in the
disease course [54]. A local ablative treatment used upfront
may prevent these adverse events, as suggested in a
retrospective analysis [55]. Local treatment, however, can
add considerable toxicity.
In men with mCNPC, there is no randomised prospective
data to support local ablative treatment of the primary.
Retrospective studies based on registries, while biased by
design, suggest a survival benefit when a local treatment is
applied upfront [56–58]. Similar findings were reported in
men with nodal disease treated locally with either RT or RP
[38,59,60]. These results have to be interpreted with caution
and treatment of the primary for this specific disease state
should only be done in the context of a clinical trial.Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. EuFifty-two percent of the panel was against treating the
primary tumour in addition to systemic therapy in men
with de novo high-volume mCNPC who are not symptom-
atic from their primary, 38% voted for treating the primary
in a minority of patients, 10% in the majority of patients in
this situation.
In the subset of panellists who voted for treatment of the
primary in this situation, 71% voted for RT, 26% voted for a
RP; 3% voted for other treatments.
4.5. Discussion of CNPC
In summary, although docetaxel-based CNPC studies have
provided evidence that some patients benefit from early
docetaxel, the field is rapidly evolving and a number of
unanswered questions have emerged [44]. Less than a third
of the panel recommended addition of docetaxel to ADT in
the majority of patients with low-volume metastatic disease
despite the fact that use of data from subgroups has
limitations and is considered hypothesis generating. Impor-
tantly, there is probably significant overlap between patients
called ‘‘low-volume’’ metastatic and ‘‘oligometastatic.’’ The
panel seemed more conservative in relation to addition of
docetaxel than in relation to local ablative treatment.
Additional studies are needed to focus on identifying
more accurate biomarkers and better understanding of the
underlying mechanisms of resistance to ADT to define a
more precise therapeutic strategy for a given biological
driver for a given APC cancer and therefore the biological
basis for the benefit of AR targeting and cytotoxic treatment
of their prostate cancer [61–63]. Moreover, if the studies of
ADT plus newer AR targeting agents such as abiraterone or
enzalutamide in the mCNPC setting, which have completed
accrual, show a benefit (NCT01715285; NCT02446405;
NCT00268476), work will be required to determine the role
of docetaxel either with ADT alone or with ADT plus the
newer hormonal therapies.
Despite the lack of prospective data from randomised
trials, a rather high percentage of the panel would consider
treatment of the primary tumour in some men with
metastatic disease. Applying such a local ablative treatment
to men with metastases in a nonresearch setting could be
‘‘excessive’’ in terms of treatment burden and is unproven
but some panellists have voted for this approach, not only in
the oligometastatic setting, but also in the general
metastatic setting, and this seems to be done in clinical
practice all over the world.
This ‘‘try it because you believe it’’ approach is well-
intentioned but may result in adverse consequences for
patients, in some cases on a large scale, as in the gross
overtreatment of low-risk localised prostate cancer. In the
era of evidence-based medicine, this approach is disappoint-
ing and we, as a scientific community, should do everything
we can to avoid having this happen again. It is worth
remembering that in other malignancies, for example, in
metastatic breast cancer, retrospective data and even a meta-
analysis had similarly suggested an OS benefit with
locoregional treatment in metastatic disease that was not
confirmed in a randomised prospective study [64]. Despiteof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34 large percentage of the panel considering treatment of
he primary in the metastatic setting, there is still an
verwhelming recommendation that this question for
rostate cancer has to be answered in prospective
andomized trials before being widely adopted in clinical
ractice. Several such trials are currently testing whether
 local definitive treatment directed to the prostate
rimary cancer can improve patient outcome in men
ith mCNPC (eg, NCT00268476, NCT01957436,
CT02454543; ISRCTN06890529).
. CRPC
.1. Sequencing and combinations in mCRPC
he field of prostate cancer drug development has seen
emarkable progress in the past 10 yr. However, this
rogress is largely based on registration studies conducted
y a ‘‘one size fits all’’ approach in a regulatory framework
hat focused on prior therapy with ADT and docetaxel
xposure rather than one defined by individual patient
iology. With current knowledge about heterogeneity in
rostate cancer, future registration trials will need to have
ore specific eligibility criteria related to the mechanism of
ction of the drug being studied.
Because the registration trials for each of these agents
ere conducted contemporaneously, the question of
equencing of the available treatment options is still
elevant. The earlier inclusion of docetaxel as part of a
hemo-hormonal therapy regimen in CNPC (section 4) may
ave implications on subsequent treatment choices. None
f the registration trials for agents in the CRPC setting
ncluded such patients.
.1.1. First-line treatment for men with mCRPC
everal prospective randomised phase 3 trials showed an
S benefit for first-line treatment in men with mCRPC. None
f the control arms used in these trials is currently
onsidered standard of care. Abiraterone, enzalutamide,
nd sipuleucel-T were evaluated as first-line agents in
symptomatic patients, docetaxel in both symptomatic
nd asymptomatic patients, and radium-223 dichloride
radium-223) in symptomatic patients with bone metasta-
es [65–70]. Sipuleucel-T is only available in the USA.
Another first-line trial testing cabazitaxel in two differ-
nt doses versus docetaxel has been reported and failed to
how superiority of cabazitaxel, but these have not yet been
ublished (NCT01308567, ASCO 2016).
There was consensus that asymptomatic men with
CRPC should receive abiraterone or enzalutamide as
irst-line treatment. This recommendation was indepen-
ent of whether they had received ADT alone (86%) or ADT
lus docetaxel (90%) in the castration-naı¨ve setting.
In case of progression within 6 mo after completion of
ocetaxel in the castration-naı¨ve setting in an asymptom-
tic man, 77% of the panellists voted for abiraterone or
nzalutamide as first-line mCRPC treatment, 17% voted for
abazitaxel, and 2% each docetaxel or platinum-based
hemotherapy (Table 6).Please cite this article in press as: Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–345.1.2. Second-line treatment for men with mCRPC
There are only prospective randomised data for second-
line treatment in men who have received docetaxel as first-
line treatment for mCRPC. In this setting, abiraterone,
cabazitaxel, enzalutamide, and radium-223 (about half
of the patients included were pretreated with docetaxel)
have shown an OS benefit [70–73]. Currently, most patients
are treated with abiraterone or enzalutamide in the first-
line setting and there is not a lot of prospective data on
second- or further-line treatment in these men.
In symptomatic men who had primary resistance to
first-line treatment with abiraterone or enzalutamide
there was a consensus (96% of the panel) for treatment
with a taxane.
In symptomatic men who had acquired resistance to
first-line abiraterone or enzalutamide there was a consen-
sus (90% of the panellists) for a taxane, 8% voted for radium-
223, and 2% had no preferred option.
In asymptomatic men with disease progression on or
after first-line docetaxel for mCRPC, there was a consensus
(92%) for abiraterone or enzalutamide as second-line
treatment. Only 6% of the panellists voted for treatment
with cabazitaxel and 2% for radium-223.
In symptomatic men with disease progression on or
after first-line docetaxel for mCRPC there was consensus
(76%) for treatment with abiraterone or enzalutamide, 18%
voted for cabazitaxel and 6% voted for radium-223
(Table 7).
5.1.3. Third-line treatment for men with mCRPC
There are no randomised prospective data for third-line
treatment in mCRPC.
In a man who has received abiraterone or enzalutamide
as first-line treatment, and docetaxel as second-line
treatment, 61% of the panellists voted for treatment with
cabazitaxel, 15% for radium-223, 8% voted for abiraterone or
enzalutamide (depending on which has already been used),
8% had no preferred choice, and 6% voted for a platinum-
based chemotherapy.
Platinum compounds have been studied in a variety of
monotherapy schedules and in different combinations
and clinical disease stages in men with APC [74]. In
unselected patients the response rates to platinum
compounds are not convincing and derived from mostly
small clinical trials.
In men with mCRPC who have exhausted approved
treatments and if no clinical trial was available a total of
96% of the panellists voted for a carboplatin-based
chemotherapy in certain situations: 33% in the majority
of patients, 2% only in patients with DNA repair defects,
14% only in patients with neuroendocrine differentiation
or clinical evidence suggestive of neuroendocrine differ-
entiation (eg, atypical pattern/distribution of metastases,
rapid progression without correlation with PSA kinetics;
sudden onset of rapid growth of visceral metastases or
multiple lytic bone metastases; presence of paraneoplas-
tic syndromes), and 47% in patients with DNA repair
defects and/or neuroendocrine differentiation or sugges-
tion thereof.Please cite this article in press as: Gillessen S, et al. Management of Patients with Advanced Prostate Cancer: The Report of the
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34.2. Treatments and schedules for mCRPC
ewer androgen-receptor pathway targeted therapies such
s enzalutamide or abiraterone carry risks of class-specific
dverse events. Abiraterone plus prednisone adverse events
nclude those related to mineralocorticoid excess, hyper-
ension, cardiac and liver dysfunction, and fluid retention.
nzalutamide can be associated with fatigue, hypertension,
ognitive and mood impairment, falls, and fractures. Both
rugs carry the risk of pharmacokinetic drug-drug interac-
ions that can increase the risk of toxicity particularly in
lder men treated with multiple other drugs.
Abiraterone and enzalutamide have been developed
lmost simultaneously and there are no published random-
sed prospective trials available that compare these two
gents against each other.
Asked about their preferred choice between abiraterone
nd enzalutamide for first-line treatment of men with
CRPC and no contraindication to either drug, 35% of the
anellists voted for abiraterone, 24% for enzalutamide, and
7% had no preferred choice.
The panellists were also asked to vote for their preferred
hoice between abiraterone and enzalutamide in patients
ith special situations (mainly comorbidities; Table 8).
There was a consensus for abiraterone over enzaluta-
ide in men with a history of falls (94%), significant
aseline fatigue (88%), and significant neurocognitive
mpairment (84%). There was consensus for enzalutamide
ver abiraterone in men with diabetes mellitus requiring
rescription drug therapy (84%; Table 8).
The preferred glucocorticoid regimen when starting
biraterone was prednisone 10 mg daily for 67% of
anellists and 5 mg daily for 27% of the panellists. Six
ercent voted for dexamethasone.
There is a retrospective analysis of patients on abirater-
ne plus prednisone who had PSA progression with or
ithout progression by imaging but in the absence of
linical progression. In these patients abiraterone was
ontinued and prednisone was switched to 0.5–1 mgTable 8 – What is your preferred choice between abiraterone and en
metastatic castration-resistant prostate cancer (mCRPC) if all option
What is your preferred choice between
abiraterone and enzalutamide at any time
in the treatment sequence in men with
mCRPC if all options are available in case
of the following medical situations?
Abiraterone
(%)
Enzalu
(%
History of falls 94 
Baseline signiﬁcant fatigue 88 
Baseline signiﬁcant neurocognitive impairment 84 
Stable brain metastases 73 
Long QTc-syndrome or men on not replaceable
drugs with potential QT prolongation
27 3
Asymptomatic men with a duration of response
to ADT (no chemo-hormonal therapy) <12 mo
6 1
Cardiac ejection fraction below 45–50 6 6
Active liver dysfunction 8 6
Diabetes mellitus requiring prescription
drug therapy
6 8
ADT = androgen deprivation therapy.
Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. dexamethasone/d. There were responses demonstrated
by PSA as well as by imaging [75,76]. The level of evidence
for this intervention is low.
In men with mCRPC who are asymptomatic and have a
rising PSA on abiraterone plus prednisone, 37% of the
panellists voted for a steroid switch to dexamethasone in
the majority of patients, 35% in a minority of selected
patients, and 26% did not vote for a steroid switch.
The pivotal trial which led to the registration and approval
of docetaxel in men with mCRPC included two regimens:
docetaxel 75 mg/m2 plus prednisone every 3 wk and a
weekly docetaxel schedule of 30 mg/m2 (d 1, d 8, d 15, d 22,
and d 29 of a 6-wk cycle) both with prednisone 10 mg
daily. There was no survival benefit of the weekly schedule
regimen compared with the other two arms, while the
side effect profile for the weekly schedule was not favourable
apart from a lower incidence of neutropenia. A smaller
phase 3 trial randomised men with mCRPC to docetaxel
3-weekly versus a 2-weekly schedule (50 mg/m2 d 1 and
d 15, every 28 d). There was a small benefit for the 2-weekly
schedule for the primary endpoint (time to treatment failure)
as well as an improvement in OS and there was a lower rate
of haematological toxicity for the 2-weekly schedule [77].
Regarding docetaxel chemotherapy for men with mCRPC
there was a consensus (86%) that the 3-weekly regimen
(75 mg/m2) should be used, 10% voted for the 2-weekly
(50 mg/m2) schedule and 4% for a weekly schedule.
The FIRSTANA trial compared cabazitaxel 25 mg/m2 to
cabazitaxel 20 mg/m2 and to docetaxel 75 mg/m2 as first-
line chemotherapy in men with mCRPC. The data were
presented (ASCO 2016; NCT01308567) but are not published
and did not show a significant difference in OS. The
PROSELICA trial was also presented at ASCO 2016 and
showed noninferiority for the primary endpoint of OS for
cabazitaxel 20 mg/m2 compared with cabazitaxel 25 mg/m2
in men with mCRPC progressing on or after docetaxel
(NCT01308580).
For cabazitaxel there was a consensus (79%) to start with
the 20 mg/m2 dose in the majority of patients, 59% ofzalutamide at any time in the treatment sequence in men with
s are available in case of the following medical situations?
tamide
)
Either (%) Neither: alternative treatment
option preferred (%)
Abstain (%)
2 4 0 0
6 6 0 0
4 10 2 0
6 10 11 0
1 24 12 6
1 56 27 0
3 27 2 2
6 14 12 0
4 10 0 0
t of Patients with Advanced Prostate Cancer: The Report of the
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EURURO 7424 1–34panellists use this dose (with dose reductions in subsequent
cycles if indicated), 20% voted for starting with this dose and
to escalate to 25 mg/m2 in the absence of relevant side
effects. Seventeen percent of the panellists voted for
starting with a dose of 25 mg/m2 in the majority of men.
In the subset of panellists who voted for cabazitaxel
25 mg/m2, 57% of the panellists voted for the use of
prophylactic WBC growth factors from start of therapy in
the majority of patients, 26% voted for the use in a minority
of selected patients, 8% voted for use of these growth factors
only for marrow toxicity occurring beyond start of therapy,
and 9% do not use them at all.
In the subset of panellists who voted for cabazitaxel
20 mg/m2, 30% voted for prophylactic WBC growth factors
from start of therapy in the majority of patients, 32% in a
minority of selected patients, 27% only for marrow toxicity,
and 11% did not vote for the use of growth factors.
5.3. Combination therapy for mCRPC
In mCRPC there are currently no combination treatment
strategies for survival prolonging agents that have shown
an OS benefit as compared with monotherapy. A number of
large randomised phase 3 clinical trials combining abir-
aterone with enzalutamide or other novel endocrine
agents and abiraterone or enzalutamide with radium-223
dichloride are currently ongoing (eg, NCT02194842M;
NCT02043678; NCT01949337). The question of combina-
tion strategies is especially relevant for radium-223,
because of the lack of antitumour activity outside of the
bone since soft tissue and visceral metastases are not
uncommon in men with APC [78].
In men with symptomatic mCRPC and bone metastases,
18% of the panellists voted for the combination of radium-
223 with either abiraterone or enzalutamide from the
beginning as a first-line treatment for mCRPC for the
majority of patients, 38% in a minority of selected patients,
and 42% of the panellists did not vote for this combination.
In men with mCRPC being treated with abiraterone or
enzalutamide for bone and soft tissue metastases and whoTable 9 – Which of the following criteria would you use to define poor p
cancer (mCRPC) putting aside pure small cell prostate cancer?
Which of the following criteria would you
use to deﬁne poor prognosis, aggressive
variant mCRPC putting aside pure small
cell prostate cancer:
Yes (%) Only in combi
with other unfav
factors (%
Neuro-endocrine differentiation on a tumour
biopsy and/or low or absent androgen
receptor expression
71 27 
Exclusive visceral metastases 70 20 
Rapid progression without correlation with
PSA kinetics
63 31 
Low PSA levels relative to tumour burden 45 47 
Predominantly lytic bone metastases 45 39 
Short response to androgen deprivation
therapy ( 12 mo) for metastatic
prostate cancer
34 60 
Bulky tumour masses 21 65 
PSA = prostate-speciﬁc antigen.
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Advanced Prostate Cancer Consensus Conference APCCC 2017. Euare progressing only in the bone, 43% of the panellists voted
for the addition of radium-223 to the majority of such
patients, 39% in a minority of selected patients, and 18% did
not vote for adding radium-223 in this situation.
In men with mCRPC treated with radium-223 and
progressing outside of the bone 52% of the panellists voted
for completing treatment with radium-223 plus adding
abiraterone or enzalutamide (if they have not received
either drug before) in the majority of patients, 20% in a
minority of selected patients, and 26% did not vote for this
approach.
5.4. Poor prognosis, aggressive variant mCRPC
While the majority of APCs remain driven by AR signalling,
it has become increasingly recognized that a subset of
mCRPC tumours may adapt during the course of therapy to
become less dependent on the AR, and this is associated
with loss of luminal prostate cancer markers (including
PSA), the development of lineage plasticity, and the
acquisition or expansion of small cell/neuroendocrine
pathologic and molecular features [79,80]. Identification
of mCRPC variants remains challenging but is often
suspected in patients that develop rapidly progressive
disease, unusual sites or pattern of metastases (eg, radio
logically lytic bone or parenchymal brain metastases), and/
or progression in the setting of a low and not or modestly
rising PSA. Metastatic tumour biopsies in this setting may
show small cell carcinoma, but are not always straightfor-
ward as mixed, atypical adenocarcinoma, and hybrid
neuroendocrine phenotypes may also occur [80].
The votes of the panellists concerning factors for
definition of poor prognosis, aggressive variant mCRPC
are reported in Table 9. There was no consensus regarding
the definition of poor prognosis, aggressive variant mCRPC.
Four percent of the panellists did not believe poor
prognosis, aggressive variant mCRPC is a clinically mean-
ingful entity.
The publication of the olaparib data in heavily pretreated
mCRPC patients with DNA repair defects in the absence ofrognosis, aggressive variant metastatic castration-resistant prostate
nation
ourable
)
No (%) I do not believe poor prognosis,
aggressive variant mCRPC is a
clinically meaningful entity (%)
Abstain (%)
0 2 0
6 4 0
4 2 0
6 2 0
14 2 0
4 2 0
12 2 0
of Patients with Advanced Prostate Cancer: The Report of the
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EURURO 7424 1–34n approved poly (adenosine diphosphate-ribose) polymer-
se (PARP) inhibitor for mCRPC has revived the interest for
he use of platinum-based chemotherapy regimens, espe-
ially in later lines. The combination of carboplatin and
ocetaxel has shown good antitumour activity in a
onrandomised phase 2 clinical trial with patients selected
or poor prognosis features [81]. A randomised phase 2 trial
f cabazitaxel plus carboplatin versus cabazitaxel alone has
een presented but is not published and showed signifi-
antly improved antitumour activity with the combination
reatment (NCT01505868, ASCO 2015).
Regarding first-line treatment of the majority of men
ith poor prognosis, aggressive variant (putting aside pure
mall cell carcinoma) 58% of the panellists voted for
tandard mCRPC treatment, 36% voted for a platinum-
nd taxane-based combination therapy, 4% for a platinum-
nd etoposide-based combination therapy, and 2% for a
latinum monotherapy.
.5. Monitoring in men with mCRPC treated with radium-223
he phase 3 radium-223 trial (ALSYMPCA) enrolled patients
ith symptomatic mCRPC [70]. Patients were randomised
o six injections of radium-223 administered every 4 wk or
o best standard of care alone. OS was improved in the
ntent to treat analysis for patients randomized to radium-
23 [70]. Substantial declines in PSA and/or lactate
ehydrogenase were uncommon in both arms. However,
lkaline phosphatase (ALP) levels showed a decline in the
adium treated patients with 87% of radium treated patients
howing some decline in ALP at wk 12 [82].
In the subset of panellists who use radium-223 in men
ith mCRPC 43% voted for testing of PSA every cycle, 43% for
very 2–4 mo; 8% voted for PSA testing only if clinically
ndicated, and 8% for no PSA testing in this situation.
Regarding ALP testing these panellists voted for either
very cycle (49%) or every 2–4 mo (37%). Eight percent
oted for ALP testing only if clinically indicated and 6%
oted for no ALP testing.
Since the ALSYMPCA trial did not mandate any imaging
or response monitoring, the role of imaging in men treated
ith radium-223 is not well documented. Symptomatic and
SA flares after radium-223 have been described and can be
ccompanied by bone scintigraphy flare [83]. Early changes
n bone scintigraphy and CT assessments tend to be
nreliable for bone response assessment and must thus
e interpreted with caution. In a retrospective series of
30 men treated with radium-223 that had baseline
maging and monitoring by imaging after three and six
ycles, the results showed a significant rate of progression
utside of the bone detected by CT scanning [83].
In the subset of panellists who use radium-223 in men
ith mCRPC there was consensus (75%) to use CT and bone
cintigraphy for staging and monitoring of men on radium-
23, while 23% of the panellists voted for one of the next-
eneration imaging methods. Regarding imaging frequency
or men treated with radium-223, 41% of these panellists
oted for every 3–4 mo, 27% voted for imaging after 6 mo
completion of radium-223) and every 3–4 mo thereafter,Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. 24% voted for imaging after 6 mo (completion of radium-
223) and follow-up imaging at progression, 4% voted for
imaging only as clinically indicated.
5.6. ‘‘Oligo-progressive’’ mCRPC
With the introduction of abiraterone and enzalutamide as
first-line treatment for asymptomatic men with mCRPC,
there are men in whom, for example, a single lymph node
progresses in size with radiological stability of the other
lesions. The term oligo-progressive is not well-defined in
APC but in lung cancer patients on novel targeted agents
such as anaplastic lymphoma kinase inhibitors there is
growing literature on definition and treatment strategies
for oligo-progressive disease [84].
There was no consensus as to the most meaningful
definition of oligo-progressive prostate cancer (mCRPC).
Forty percent of the panel voted that they did not believe in
oligo-progressive disease as a meaningful clinical entity,
33% voted for the definition of only one progressing pre-
existing lesion with otherwise stable/responding metastatic
disease, 23% voted for 3 progressing pre-existing lesions
with otherwise stable/responding metastatic disease.
The subset of the panel who believed in oligo-progres-
sive mCRPC voted on biopsy of a progressing lesion (for
diagnostic purposes). Twenty-nine percent of the panellists
voted for a biopsy in the majority of patients, 52% for a
biopsy in a minority of selected patients (eg, from visceral
metastases), while 19% did not vote for a biopsy. These
panellists also voted on the treatment for men with oligo-
progressive mCRPC: 40% voted for a change or addition of
systemic therapy without local treatment, 47% for local
treatment of the progressing lesion(s) while continuing
systemic therapy unchanged, and 13% for local treatment of
the progressing lesion(s) plus adding or changing the
systemic treatment.
5.7. Discussion of CRPC
We have witnessed the successful development of agents
including the novel androgen signalling inhibitors abir-
aterone and enzalutamide for earlier stage mCRPC. More
recently, a significant survival advantage by introducing
docetaxel treatment was confirmed. It thus appears that we
are moving our therapies earlier in the disease, while the
question of optimal sequencing of the treatment options is
still unanswered. We know that a distinct subset of patients
will not respond to treatment also depending on the
sequence, or may experience unwarranted toxicity. More-
over, it is possible that with the appropriate sequencing we
may augment the OS benefit of our patients.
Treatment sequencing in APC is governed by a number of
parameters that unfortunately do not yet serve the ultimate
goal of maximizing clinical outcome. Clinical decision-
making is still largely dependent on local reimbursement
policies and on a number of variables that are not truly
objective. There are no validated clinical or molecular
predictive markers for guiding our choice thus predeter-
mining a more favourable cost/benefit ratio for our patients.t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34Increased benefit is encompassing longer life with im-
proved quality whereas minimising cost including compo-
nents such as toxicity, financial burden, and uncertainty.
Choices made in the clinic are in part based on objective
data such as available level I evidence and access to agents.
Yet, professional speciality and experience affect these
choices. The presence or absence of symptoms clearly
influenced treatment selection for the panellists.
We are also being challenged by the as-yet unproven
hypothesis that combinatorial approaches may enhance
outcome by potential synergistic activity or delay of
resistance to treatment. We are anticipating results from
several relevant phase 3 trials and should therefore avoid
implementation of such approaches as long as they are
unproven especially since concerns for toxicity arise.
Regarding the aggressive variant of CRPC, the majority of
the panel recognises its existence and that it is important to
recognise it since these patients may be less likely to
respond to subsequent AR-directed therapies; however,
there was no consensus for the exact definition. With a
more profound and eventually earlier suppression of AR
pathways in the disease history, identifying and treating AR
independent variants will become increasingly important
[85]. The development of robust biomarkers is an area of
active research. We may need a combination of clinical and
molecular features to identify aggressive variants, encom-
passing but not limited to those with neuroendocrine
carcinoma morphology detected on biopsy, as targeted
treatment approaches based on a molecular subclassifica-
tion of APC are developed. Understanding the role of DNA
repair in contributing to the phenotype, mediating PARP
inhibition, and also platinum sensitivity and potential
immunotherapy treatment sensitivity is also important.
6. Imaging in APC
Reproducible and validated methods for detecting and
quantifying metastatic disease are needed to manage
patients with APC. Currently, recommended methods of
metastatic imaging assessment, that is, with bone scintig-
raphy and CT scans, have significant limitations in detecting
metastases as well as in monitoring response to treatment
but remain the standard of care in most settings [1,21,
86–89]. Due to limitations in systematically conducted
prospective studies, the use of next-generation imaging has
not been shown to impact on clinical outcome.
6.1. Nodal disease assessments in APC
Morphologic assessments for possible nodal disease using
CT and MRI scans are based on the evaluation of detected
nodes based largely on size criteria. Other morphologic
criteria, such as the nodal shape, loss of nodal hilum fat,
clustering, extranodal disease, and enhancement character-
istics can serve as additional aids to diagnosis. Unfortu-
nately, morphologic imaging is unable to identify
micrometastases or to distinguish large hyperplastic benign
from malignant nodes. Thus, the general test performance
of morphologic imaging remains limited when histologicPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eucorrelations using template lymphadenectomy are used as
the standard of reference. A meta-analysis showed a CT scan
sensitivity of 42% and specificity of 82%, while morphologic
MRI had a sensitivity of 39% and a specificity of 82%
[90]. While positron emission tomography (PET)/CT has
improved sensitivity, it is important to keep in mind that
the spatial resolution of PET/CT is approximately 4 mm.
6.2. Bone disease assessments in APC
For the sensitive detection of metastatic bone disease, the
use of current recommendation of bone scintigraphy and CT
scans has low sensitivity and specificity [91].
Systematic analyses, prospective clinical studies, and
meta-analyses have shown comparative test performance
of whole-body diffusion weighted MRI (WB-MRI) to NaF
and choline PET/CT for the skeletal assessments in APC
[92,93]. A recent meta-analysis underlined the usefulness of
diffusion weighted MRI as a method that improves the MRI
detection of bone metastases [94]. When evaluating the
results of the above meta-analyses and indeed in all studies
reporting test performance, the readers should note that
there are intrinsic verification biases that are particularly
prevalent at lesion level analyses, because it is not possible
to obtain histopathology for every bone lesion detected. As a
result, most studies are patient level analyses, using
combinations of imaging methods and/or follow-up as
the standards of reference [91,92].
PET/CT can detect a larger number of skeletal lesions
than bone scintigraphy [95]. Regarding the PET/CT tracers
comparative studies between prostate-specific membrane
antigen (PSMA) and choline have demonstrated superiority
of PSMA to identify bone lesions [96]. The PET tracer 18F-
fluciclovine has recently been approved for use in North
America; available data indicate good detection rates both
for lymph nodes and for bone disease in biochemical
recurrence of prostate cancer [97]. The diagnostic perfor-
mance of fluciclovine PET was found to be superior to CT
and to choline PET but there are no comparative data versus
WB-MRI and PSMA PET [98].
Importantly, all our prognostic models and clinical
trials in APC were developed using CT scan and bone
scintigraphy and the essence of detection of disease at
diagnosis is one of risk determination. Next generation
imaging may have superior performance characteristics
compared with older modalities, but clinical validation with
regard to the question of impact on outcome has not yet
been performed.
6.3. Imaging for locally advanced prostate cancer
In men presenting with high-risk or locally advanced
prostate cancer and with biochemical recurrence after local
therapy, imaging to document potential metastases may be
important. At this state of the disease metastases are most
commonly located within regional (N1) and nonregional
lymph nodes as well as in bone (M1).
There was no consensus regarding the imaging modality
to ‘‘exclude’’ distant metastases in high-risk and locallyof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
1396 a
1397 c
1398 p
1399 v
1400 f
1401 6
1402 C
1403 a
1404 p
1405 p
1406 
1407 C
1408 r
1409 r
1410 r
1411 l
1412 v
1413 b
1414 o
1415 [
1416 c
1417 
1418 i
1419 p
1420 l
1421 p
1422 d
1423 i
1424 
1425 S
1426 p
1427 m
1428 w
1429 w
1430 
1431 d
1432 c
1433 b
1434 t
1435 d
1436 f
1437 p
1438 P
1439 M
1440 b
1441 
1442 7
1443 s
1444 m
1445 s
1446 o
1447 a
1448 i
1449 
1450 i
1451 d
1452 m
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X18
EURURO 7424 1–34dvanced prostate cancer: 41% of the panel voted for a
ombination of CT and bone scintigraphy, while 47% of the
anel voted for next-generation imaging methods (37%
oted for a PET/CT with any of the tracers PSMA, choline, or
luciclovine and 10% voted for a WB-MRI).
.4. Imaging in the setting of BCR (PSA)
linical symptoms and PSA alone are not good indicators for
bsence of metastases, with 32% of clinical M0 CRPC
atients being found to be metastatic when imaging was
erformed [99].
Regarding PET/CT in BCR, a meta-analysis including both
-11 and F-18 choline-based techniques reported detection
ates greater than 50% for PSA values above 2 ng/ml, with
apid PSA kinetics and elevated Gleason score positively
elated to higher detection rates [100–103]. The main
imitation of choline PET/CT is the low sensitivity when PSA
alues are <1 ng/ml. In BCR there are comparative studies
etween Ga-PSMA and choline demonstrating the superi-
rity of Ga-PSMA in terms of detection rates at any PSA level
104–106]. Guidelines (NCCN, EAU) have mentioned
holine PET/CT in the situation of BCR [21,22].
The use of next-generation imaging modalities has led to
dentification of metastatic foci at lower PSA levels. Treating
hysicians may feel more comfortable offering ablation of
imited metastases in these cases, but as of now there are no
rospective data to show that earlier detection of metastatic
isease with next-generation imaging results in a mean-
ngful long-term clinical improvement.
Imaging in men with rising PSA after RP before starting
RT was voted for by 44% of the panellists in the majority of
atients independent of PSA level, by 29% of panellists in
en with a PSA >0.5 ng/ml, by 12% of the panellists in men
ith a PSA >1 ng/ml and by 13% of the panellists in men
ith a PSA >2 ng/ml.
For imaging in men with oligometastatic recurrent
isease after local treatment for prostate cancer with
urative intent ( SRT), 78% of the subset of panellists who
elieved in the oligometastatic recurrent state voted for one of
he next-generation imaging methods to detect metastatic
isease: namely 47% voted for a PET/CT (PSMA, choline, or
luciclovine) alone, 2% voted for a WB-MRI alone, 25% of the
anel members voted for a combination of a pelvic MRI and a
ET/CT, 4% of the panellists voted for a combination of a pelvic
RI and a WB-MRI, and 22% of the panellists voted for imaging
y CT and/or MRI and bone scintigraphy.
In men with de novo apparent oligometastatic disease,
2% of the subset panellists who believed in the oligometa-
tatic state voted for one of the next-generation imaging
ethods to support this diagnosis (apart from local
taging): namely 34% voted for a PET/CT (PSMA, choline,
r fluciclovine), 4% voted for a WB-MRI, 34% voted for either
 PET/CT or WB-MRI, and 26% of these panellists voted for
maging by CT and/or MRI and bone scintigraphy.
Asked about the recommended tracer in case of a PET/CT
n men with apparent oligometastatic castration-naı¨ve
isease, there was a consensus (76%) amongst the panel
embers for PSMA as tracer, 10% voted for fluciclovine as aPlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. tracer, and 6% voted for choline; 4% of the panellists voted
for any of the three tracers.
In men with rising PSA on ADT (CRPC) and potentially
oligometastatic disease, 74% of the subset of panellists who
believe in oligometastatic disease in mCRPC voted for one of
the next-generation imaging methods to confirm this
diagnosis: namely 48% voted for a PET/CT (PSMA, choline,
or fluciclovine), 6% voted for a WB-MRI, 18% of the panel
members voted for a combination of a pelvic MRI and a PET/
CT, 2% of the panellists voted for a combination of a pelvic
MRI and a WB-MRI, and 26% of the panellists voted for
imaging by CT and/or MRI and bone scintigraphy.
6.5. Staging and monitoring in mCNCP
In mCNPC, what is required is an imaging modality that
confirms the presence of metastases and defines their
location. This is important for assessing prognosis and for
treatment decisions. Current guidelines (NCCN, EAU) do not
comment on imaging methods for men with mCNPC
because of lack of data.
In mCNPC, 51% of the panel voted for baseline imaging
and follow-up imaging at PSA nadir/completion of six cycles
of docetaxel as part of chemo-hormonal therapy and again
at progression (confirmed PSA rise and/or clinical progres-
sion), 31% of the panel voted for baseline imaging and
regular monitoring by imaging every 3–6 mo, and 18% of the
panel voted for baseline imaging only and monitoring by
PSA alone with further imaging at progression.
Regarding the recommended imaging modality for
staging and monitoring of men with mCNPC, 73% of the
panel voted for CT and bone scintigraphy and 25% of the
panellists voted for one of the next-generation imaging
methods.
6.6. Staging and monitoring in mCRPC
The early identification of treatment failure in men with
mCRPC on systemic therapy would help in sparing some
patients futile treatment and potential toxicity as well as in
reducing the costs of ineffective treatments and decreasing
the time to initiation of a next-line, potentially effective
treatment [107]. Recent data indicate that there are a
substantial number of patients who have radiographic
progression without PSA progression, including some
patients with aggressive variant prostate cancer [108,109].
Imaging before treatment initiation and on-therapy may be
important in predicting both benefit and more importantly
nonbenefit of treatments.
An ideal imaging method to monitor response to therapy
should enable the evaluation of tumour cell viability,
especially for bone disease. Techniques such as bone
scintigraphy, CT scans, and NaF PET rely on tumour matrix
interactions and are only indirect indicators of tumour cell
viability. Imaging assessments should always be combined
with clinical status and other factors as also recommended
by the PCWG3 group [108,107].
For monitoring by imaging in men with mCRPC on first-
line therapy, 54% of the panel voted for baseline imagingt of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34and regular monitoring by imaging every 3–6 mo, 28% of the
panellists voted for baseline imaging and follow-up imaging
at PSA nadir and again at progression (confirmed PSA rise
and/or clinical progression); 16% of the panel voted for
baseline imaging only and monitoring by PSA alone with
further imaging at progression.
Regarding imaging modality for staging and monitoring
in men with mCRPC, 74% of the panel voted for CT and bone
scintigraphy and 24% of the panellists voted for one of the
next-generation imaging methods.
For monitoring of patients with a diagnosis of aggressive
variant mCRPC, 62% of the panellists voted for standard
imaging by CT and bone scintigraphy, 2% voted for CT alone,
and 36% voted for next-generation imaging modalities.
6.7. Discussion of imaging in APC
There are sufficient data indicating that next-generation
imaging technologies have better accuracy for detecting
metastases than CT and bone scintigraphy. However, their
current use is dependent on costs, local availability, and
expertise of interpretation and the better accuracy has not
been shown to correlate with improvement of clinical
outcomes.
The performance of PET/CT with new tracers (PSMA and
fluciclovine) as indicators of treatment efficacy and as
predictors of patient outcome has yet to be assessed. PSMA
PET/CT should be interpreted with caution since there are
data suggesting correlation between PSMA expression and
AR signalling [110–115]. Tumour foci not expressing PSMA
(or lesions in organs with high PSMA expression, eg, liver)
may not be assessable for response using PSMA PET/CT.
Notably, other tumour types (eg, lung cancer, renal cell
cancer) and nonmalignant processes like Paget’s disease
and haemangioma can express PSMA [116,117].
The use of these next-generation imaging modalities
may be especially valuable in situations where the tumour
burden assessments are needed for treatment decisions
and/or when high sensitivity is a requirement. This may be
particularly applicable when multimodality salvage thera-
py is being considered. However, the proof that their use
leads to better treatment decisions and ultimately leads to
improved outcomes is pending also in this situation.
For evaluation of response in men with mCRPC it is
evident that next-generation imaging (MRI and PET) may
prove to be more accurate for evaluating response to
treatment [118]. However, it should be noted that the
recently published PCWG3 do not recommend the routine
use of next-generation imaging methods for men with APC
treated on clinical trials mainly due to the lack of
availability, outcome data, and standardisation across
global sites [107]. The recently published guideline on
reporting WB-MRI in men with APC is a step into the right
direction but these recommendations need to be adopted,
applied, and validated in clinical trials with primary
endpoint of clinical outcome [86]. As an example, the
systematic evaluation of FDG-PET studies in patients with
Hodgkin’s disease has resulted in a reduction in treatment
intensity leading to reduction of toxicity [119]. Such trialsPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Euwith next-generation imaging are largely missing in men
with APC [120].
The clinical introduction of potentially impactful imag-
ing technologies has created an opportunity for progress by
linking anatomy to underlying biology but there is also a
risk of up-staging of many men in every disease state. The
contribution of the next-generation imaging techniques to
the welfare of patients depends on performance for the
purpose they are being applied (‘‘fit for use’’) and their
clinical utility (patient benefit). The early assessment of
new technologies is therefore encouraged but their general
acceptance before measures of performance and evidence of
benefit are at least estimated should not be supported.
Novel imaging techniques should be clinically deployed
ideally in a trial setting but at least in registries with the goal
of efficiently estimating performance and utility. Finally, it
is important to recognise that the clinical trials that form
the basis of the currently approved treatment options are
based on evaluations with CT and bone scintigraphy.
7. Use of osteoclast-targeted therapy for SRE/SSE
prevention for mCRPC (not for osteoporosis/bone loss)
In prostate cancer, two bone-directed agents, zoledronic
acid—a bisphosphonate—and denosumab—a receptor acti-
vator of nuclear factor kappa-B ligand inhibitor—have been
shown to prevent or delay the onset of SREs. Neither of the
drugs influences OS or PFS significantly [121,122].
Of the bisphosphonates, zoledronic acid is the only one
that has shown a protective effect against SRE in patients
with mCRPC [122,123]. Denosumab is a fully human
monoclonal antibody that specifically targets receptor
activator of nuclear factor kappa-B ligand thus effectively
inhibiting osteoclast function and bone resorption. In the
setting of mCRPC, denosumab (120 mg subcutaneous every
4 wk) compared with zoledronic acid (4 mg intravenous
every 4 wk) significantly improved the time to first SRE
[121].
At the present time, these agents have proven relevant
efficacy only in patients with bone mCRPC. There is no
evidence to support their use in the nonmetastatic CRPC
setting and there is evidence not to use it in the mCNPC
setting apart from osteoporosis prevention, using a different
regimen, and dosage for both drugs [43,124,125].
When looking at SSE, two prospective randomised
studies in men with mCRPC demonstrated an advantage.
The TRAPEZE study showed a significant delay in SSEs when
docetaxel was combined with zoledronic acid as compared
with docetaxel alone and that the combination was safe, but
there was no improvement in OS [126]. Interestingly, the
benefit in delaying SSEs was in the same range as what was
seen in the pivotal zoledronic acid study when chemother-
apy was not in use. Also, the recent analysis of the large
pivotal denosumab trial confirmed a benefit in preventing
SSEs [127]. Hypothesis-generating results have been pre-
sented from the ALSYMPCA trial where the subgroup of
patients receiving a combination of radium-223 plus an
osteoclast targeted therapy had a significant reduction in
SSE compared with radium-223 alone [70,128].of Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34In an era of life prolonging therapies for mCRPC that can
lso prevent or delay SREs, the added benefit of osteoclast
nhibitors is difficult to estimate given the limited number
f well designed, adequately powered studies with long
erm follow-up.
Regarding the frequency of administration of these
one-directed agents a recent randomised trial in different
umour types also including 689 men with prostate cancer
howed no increased risk of skeletal events with zoledronic
cid every 12 wk compared with every 4 wk [129]. However,
he proportion of patients with CNPC versus CRPC is not
eported and both were accrued to the trial. No firm
onclusions can be made from this trial because of this
ariable.
For reducing the risk of skeletal complications in men
ith mCRPC and bone metastases, 86% of the panel were in
avour of some form of osteoclast-targeted therapy, 54% of
he panel voted for denosumab, 8% voted for zoledronic
cid, 24% of the panellists voted for either zoledronic acid or
enosumab, and 10% did not vote for an osteoclast-targeted
herapy at all.
Of those panellists who voted for an osteoclast-targeted
herapy in men with mCRPC, 68% voted for a treatment
uration of about 2 yr and 32% voted for no limitation of
reatment duration.
The question of frequency and duration of osteoclast-
argeted therapy in the absence of significant toxicity for
symptomatic men with mCRPC and bone metastases
esponding to first-line systemic mCRPC treatment is not
esolved.
In the subset of panellists who voted for osteoclast-
argeted therapy in men responding to first-line mCRPC
herapy, 17% of the panellists voted for every 4 wk
ithout a defined maximum duration, 37% voted for
very 4 wk for approximately 2 yr and then less
requently, 15% voted for every 3 mo, and 27% of the
anel did not vote for an osteoclast-targeted therapy in
his situation. In the same patient population, but when
hese men are no longer responding to first-line therapy,
7% of the panellists voted for osteoclast-targeted
herapy every 4 wk without a defined maximum duration
nd 53% of the panel voted for every 4 wk for about 2 yr
nd then less frequently.
Osteonecrosis of the jaw (ONJ) is a possible severe side
ffect of osteoclast-targeted therapy that increases with the
uration of treatment [130,131]
In men with mCRPC who develop ONJ while on
steoclast-targeted therapy, there was consensus (84%)
o discontinue osteoclast-targeted therapy permanently
hile 16% of the panellists voted for discontinuation of the
steoclast-targeted therapy and restarting after complete
ound healing.
.1. Discussion of the use of osteoclast-targeted therapy for
RE/SSE prevention for mCRPC
he optimal timing, schedule, and duration for osteoclast-
argeted therapy and the overall balance of benefit and risk
s well as efficacy in the era of novel mCRPC treatments arePlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. still a matter of debate as there is no Level I evidence to
guide decision making.
Effective osteoclast inhibitors are commonly recom-
mended as part of the overall therapeutic approach to
mCRPC also in an era of multiple life prolonging agents.
Their use in combination with approved life prolonging
mCRPC treatments may enhance their utility in terms of
reducing the risk for of skeletal complications and to
maintain quality of life—but these data have been derived
from posthoc and subgroup analyses and need to be
addressed in prospective clinical trials. In daily clinical
practice, the risk of side effects—especially ONJ—which
increases with duration of therapy, the early use of
osteoclast-targeted therapy for men with mCRPC has to
be weighed up against the potential benefit of reduction in
risk of SRE/SSE [131].
8. Molecular characterisation
8.1. Tumour biopsy in APC
Since clinical heterogeneity is common, mCRPC tumour
biopsies should be reviewed and interpreted in the
appropriate clinical context. This is especially important
for uncommon yet challenging cases with small cell or
neuroendocrine differentiation or tumours that lack ex-
pression of classical prostate markers such as PSA or AR.
Furthermore, not all patients with clinical features sugges-
tive of androgen independence demonstrate small cell or
neuroendocrine features on tumour biopsy although they
may still benefit from platinum based chemotherapy. These
data may potentially be explained by molecular overlap
with neuroendocrine prostate cancer [79,132].
Moving forward, incorporating molecular biomarkers
will likely improve the clinical diagnosis of non-AR driven
mCRPC and may help in patient selection for current
therapies and selection for biomarker stratified clinical
trials [132–138]. Genomic alterations enriched in mCRPC
with emerging prognostic and/or treatment implications
include AR gene mutation and amplification, phosphoinosi-
tide 3-kinase/Akt/phosphatase and tensin homolog path-
way alterations, DNA repair defects including loss of
homologous recombination (eg, BRCA1/2, ATM), and
mismatch repair (with microsatellite instability [MSI] and
hyper-mutated phenotype), TP53 deletion/mutation, and
RB1 loss [132,138–142]. Alterations involving RB1 and TP53
are universal in small cell cancers arising elsewhere in the
body, such as the lung cancer, and are enriched in prostate
cancer patients with luminal to basal cell lineage switching
and neuroendocrine biomarker expression and are mecha-
nistically involved in the development of ‘‘androgen
indifferent’’ resistance [134,137,138,141].
The panel voted on molecular factors that should be
reported in a tumour biopsy in men with mCRPC apart from
reporting tumour morphology (Table 10).
There was a consensus (78%) that BRCA1, BRCA2, and ATM
mutations should be reported because that knowledge will
likely influence management decisions. For all other factors
there was no consensus (Table 10).t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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Table 10 – As a clinician, which factors do you want to have reported back to you in men with metastatic castration-resistant prostate cancer
who undergo a metastatic tumour biopsy apart from tumour morphology and differentiation? The question is only about management for a
specific patient, not about familial implications, and based on knowledge in terms of test accuracy/validity and available treatments
Factor Yes, useful test for majority
of patients (inﬂuences your
management decision; %)
Only for minority of
selected patients (%)
No (%) Abstain (%)
BRCA1, BRCA2, and ATM mutations 78 20 2 0
PSA IHC 72 18 10 0
Other DNA repair genes (eg, CHEK2,
PALB2, and others)
64 22 12 2
MMR gene alterations (MSI, MMR
protein IHC, or by direct sequencing)
54 22 20 4
Chromogranin, synaptophysin, CD56/NSE 50 31 17 2
Loss of PTEN 44 26 26 4
AR ampliﬁcation and/or AR mutation 43 18 37 2
TP53 and RB1 34 22 40 4
Nuclear AR 34 18 46 2
AR-V7 33 26 37 4
PSMA 32 22 44 2
Ki67/MiB1 28 26 42 4
Prostate acid phosphatase 26 18 54 2
1PD-1/PD-L1 22 31 45 2
NKX3.1 12 33 49 6
1ERG IHC 12 30 56 2
ERG FISH 11 23 64 2
AR = androgen receptor; FISH = ﬂuorescent in situ hybridization; IHC = immunohistochemistry; MMR = mismatch repair; MSI = microsatellite instability;
PD-1 = programmed cell death-1; PD-L1 = programmed death-ligand 1; PSA = prostate-speciﬁc antigen; PSMA = prostate-speciﬁc membrane antigen;
PTEN = phosphatase and tensin homolog.
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 21
EURURO 7424 1–348.2. Androgen receptor splice variant-7 and AR amplification/
mutation
Using liquid biopsies on mCRPC patients starting abirater-
one or enzalutamide, statistically significant associations
with worse outcome have been reported for detection of AR
splice variants including the AR-V7 transcripts in circulat-
ing cells or in exosomes, AR-V7 protein in the circulating
tumor cell nucleus, or by analysing plasma cell-free DNA AR
gene copy number gain assessed via cell-free DNA or
somatic point mutations similarly quantified [143–148].
All studies to date were single-arm trials, and statistically
significant associations with response were noted—
although the correlation with response has focused largely
on rates of PSA declines. Moreover, evidence remains that
some men with AR-V7 positive mCRPC may still respond to
abiraterone/enzalutamide.
There was a consensus (96%) not to use AR-V7 testing in
daily routine clinical practice for the majority of men with
mCRPC. Similarly, there was a consensus (92%) not to use
cell-free DNA AR amplification and AR mutation testing in
daily routine clinical practice for the majority of men with
mCRPC.
8.3. Somatic mutations
Recent genomic studies of metastatic prostate cancer have
identified new molecular targets in the AR signalling
pathway, phosphoinositide 3-kinase pathway, WNT path-
way, cell cycle pathways, and perhaps most importantly, in
DNA repair pathways [133,139,149].
Fifty-nine percent of the panellists did not vote for DNA
sequencing of tumour biopsies in the majority of men withPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. EumCRPC in routine daily clinical practice, 37% of the
panellists voted for a targeted/panel sequencing approach,
and 4% voted for whole genome or exome sequencing.
8.4. DNA repair testing in daily routine clinical practice
Recent studies have shown that men with APC commonly
have somatic aberrations of genes that make up various
elements of the DNA repair machinery with 20–30% of APCs
having loss of function of proteins implicated in homolo-
gous recombination repair, including BRCA2, BRCA1, ATM,
PALB2, and others [139]. These aberrations lead to
homologous recombination deficiency (HRD) detectable
by next-generation sequencing of these genes or of the
genomic scars resulting from this repair defect estimated as
an HRD score. A clinical trial (TOPARP) of the PARP inhibitor,
olaparib, has shown antitumour activity against prostate
cancers with HRD [140].
HRD defects have been previously reported to sensitise
tumour cells to platinum-based chemotherapy [150]. Clini-
cal data are now emerging that HRD defects in prostate
cancers also sensitise to platinum-based chemotherapy
[151] in keeping with previous reports that satraplatin has
antitumour activity against this disease [74,152].
Somatic deleterious aberrations of mismatch repair
genes (MSH2, MSH6, MLH1, PMS2) have been found in
APC, and are possibly associated with ductal pathology,
although their precise frequency remains uncertain and is
in the range of 5% to 15% [142,153,154].
8.4.1. DNA repair defects in CNPC
The presence of DNA repair defects (germline or somatic) in
men with newly diagnosed mCNPC does not change theof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34tandard treatment recommendation for 49% of the panel.
wenty-three percent of the panellists were more likely to
ive docetaxel in addition to ADT and 22% of the panel were
ore likely to include a platinum agent in the chemo-
ormonal treatment regimen.
.4.2. DNA repair defects in mCRPC
hen testing for DNA repair defects was considered for
en with mCRPC, and no recent mCRPC tissue biopsy tissue
as available, 70% of the subset of panellists who supported
esting in this situation voted for a fresh mCRPC tumour
iopsy, 16% of the panellists voted for testing in archival
issue, and 14% voted for testing in circulating cell-free DNA.
Sixty-five percent of the panel voted for treatment with
laparib, or another PARP inhibitor if available and
pproved, in men with mCRPC and the presence with
NA repair defects (germline or somatic) based on the
hase 2 data with olaparib, 29% of the panel voted for such
reatment in a minority of selected patients and 4% did not
ote for it at all.
Some panel members voted that it was appropriate to
xtrapolate the phase 2 data from olaparib to platinum
gents for men with mCRPC and presence of DNA repair
efects (germline or somatic): 45% in the majority of
atients and 14% in a minority of selected patients; however
5% of the panellists did not support this extrapolation.
Sixty-seven percent of the panel voted for standard first-
ine mCRPC therapy in men with mCRPC and presence of
NA repair defects (germline or somatic) progressing on
DT, 21% of the panellists voted for a platinum-based
ombination, and 10% for a PARP inhibitor.
In men with mCRPC and a presence of DNA repair defects
n the second-line setting (after standard first-line therapy),
0% of the panellists voted for a platinum-based combina-
ion, 33% of the panel voted for standard second-line mCRPC
reatment, 21% for treatment with PARP-inhibitor, and 4%
or a platinum monotherapy.
.5. Discussion of molecular characterisation
iven men with mCRPC are surviving longer, and with
everal treatment options available, biopsies of metastatic
esions are more commonly pursued to rule out small cell
arcinoma, an aggressive variant, or a second malignancy.
ut the real place for metastases biopsy remains unclear in
veryday practice. With a multitude of potential predictive
nd prognostic markers that can be tested in a mCRPC
umour biopsy, it is important to provide some guidance. As
f March 2017, there was only consensus from the panel for
esting of BRCA1, BRCA2, and ATM mutations in mCRPC
issue.
Several registration trials are now being conducted with
ifferent PARP inhibitors for men with APC and evidence of
NA repair defects (eg, NCT02952534, NCT02975934,
CT02854436, NCT03012321) and in the absence of
pproved PARP inhibitors for mCRPC, enrolment of men
n clinical trials is strongly recommended.
Additionally, there are also prospective trials of platinum-
ased therapy ongoing in men with advanced molecularlyPlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. selected prostate cancers, which may demonstrate that this
is an important therapeutic strategy for this subgroup of
patients (eg, NCT02598895, NCT02311764, NCT02955082).
Although true MSI is rare in prostate cancer, its presence
is important because MSI+ cancers have a high rate of
durable responses to immune checkpoint blockade using
drugs that block the programmed cell death-1/programmed
death-ligand 1 interaction [155]. Based partly on a
biomarker selected ‘‘basket’’ trial (NCT02628067), it is
possible that pembrolizumab may be agency-approved for
use in MSI+ cancer patients regardless of histology—such
an approval will be of clear interest to clinicians and to the
3–7% of patients with true MSI+ prostate cancer.
Although a proportion of the panel voted for using a
PARP inhibitor or platinum-based chemotherapy in mCRPC,
even in the first-line setting, there is no evidence that such a
strategy is of advantage as compared with the standard
approved mCRPC treatments to date. Therefore, in the
absence of prospective randomised trials showing clinical
benefit for a strategy using a PARP-inhibitor or a platinum-
based chemotherapy, the use of these substances as first-
line mCRPC treatment outside of clinical trials should not be
generally recommended.
For the liquid biomarkers, namely AR-V7 and AR
mutation or amplification, there was a consensus that
currently none of these markers should be tested in routine
practice for decision making. This consensus against testing
is in part based upon the low detection levels of AR-V7 prior
to first- and second-line therapies and the high probability
that patients would receive abiraterone or enzalutamide in
this situation. These tests need to be validated and further
studies need to be performed to determine their impact on
long-term outcomes.
9. Germline genetic counselling/testing
The aetiology of prostate cancer is not well understood,
although epidemiological studies demonstrating a conver-
gence of incidence rates in some populations migrating
between areas with a low incidence to those with high
incidence suggest environmental and lifestyle risk factors
play a role [156]. Having a positive family history and/or a
certain ethnic background such as Afro-Caribbean is a risk
factor for prostate cancer development. Evidence from
studies where monozygotic twins were compared with
dizygotic twins suggest that 57% of the risk of prostate
cancer prostate cancer is due to genetic factors [157]. Nu-
merous studies of risks to relatives of prostate cancer cases
show a higher relative risk of developing prostate cancer,
which increases as the age of the proband decreases, and the
number of affected relatives increases. First degree relatives
of prostate cancer patients have twice the risk of developing
the disease compared with the general population [158]. In
men diagnosed under the age of 60 yr, the risk to their first
degree relatives is more than fourfold that of those without
a family history [159]. The variation in incidence according
to ethnicity also suggests a genetic component; rates are
higher in African American men compared with Asian-
American men [160].t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34Studies of familial inheritance and segregation analyses
have proposed various genetic models (autosomal domi-
nant, recessive, and X-linked) [161]. It is now recognised
that genetic predisposition to prostate cancer is composed
of common (> 5%) lower risk variants single nucleotide
polymorphisms—most of which are not in coding regions
and rare higher risk variants (coding mutations in genes).
Over 100 single nucleotide polymorphisms associated with
the development of prostate cancer have been identified
thus far [162].
Rarer variants are those which have a minor allele
frequency of <5%, and occur too infrequently to be detected
on a genome-wide association study. Next-generation
sequencing of targeted areas or whole genome/exome
sequencing has enabled the detection of these rare variants.
Results showed that men from families where females had
developed breast and ovarian cancer caused by BRCA
mutations have a five-fold relative risk of prostate cancer
when they harbour a germline BRCA2 mutation compared
with men without a mutation. This relative risk increases to
up to seven-fold if the men in the family develop prostate
cancer below the age of 65 yr [163]. In a larger study,
2000 men with prostate cancer were screened. This showed
that just over 1% of men who developed prostate cancer
below the age of 65 yr carried a deleterious BRCA2 mutation
and often they did not have a positive family history
[164]. For men who are carriers of a BRCA1 mutation, studies
have shown that there is an approximately four-times
relative risk of developing prostate cancer for men aged
under 65 yr compared with those without the mutation
[165]. It has been subsequently shown in men with a family
history of at least three cases of prostate cancer that they
have a germline mutation in DNA repair genes in 7.3% and
that the disease was more likely to be aggressive [166].
Several groups have shown that BRCA1 and two mutation
carriers have a more aggressive form of prostate cancer and
also have a worse prognosis [167,168]. Mutation carriers
are also likely to present with a higher risk of local nodal
involvement as well as with distant metastatic disease
[169]. The optimal radical treatment option for these
patients is yet to be determined, but RP may be the most
suitable, although the numbers of patients studied are
relatively small [170].
Remarkably, germline mutations have been found in
about half of the men with tumour HR DNA repair gene
defects and about one in five men with an mismatch repair
DNA repair gene defect [139,171]. In a large multi-
institutional study of almost 700 men with metastatic
prostate cancer unselected for age or family history, 11.8%
overall were found to have moderate or high penetrance
germline mutations in one of 16 DNA repair genes, with
7.8% of mutations in BRCA2, BRCA1, and ATM [171]. Two
large single-institution studies of metastatic prostate
cancer found similar rates of germline BRCA2, BRCA1, and
ATM mutations, with much lower rates in low risk indolent
disease [172,173].
Regarding genetic counselling and testing for men with
newly diagnosed metastatic prostate cancer, 20% of the
panel voted to do it in a majority of patients: 62% ofPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Euthe panel voted in favour of genetic counselling/testing
in a minority of selected patients and 18% did not vote to do
it at all.
The subset of panellists who had voted for genetic testing
in a minority of selected patients supported genetic
counselling and testing in men with a positive family
history for prostate cancer (95%); also, 93% of these
panellists supported counselling/testing in men with a
positive family history for other cancer syndromes (eg,
hereditary breast and ovarian cancer syndrome and/or
pancreatic cancer or Lynch syndrome). Further, 74% of these
panellists voted for genetic counselling and testing in men
with prostate cancer diagnosed at 60 yr but 26% of these
panellists did not vote for genetic counselling and testing
based on an age cut-off alone.
Among the subset of panellists who recommended
genetic testing, 61% voted for large panel testing including
homologous recombination and mismatch DNA repair (eg,
comprehensive cancer risk assessment panels), 15% voted
for BRCA1 and BRCA2 testing only, 14% voted for BRCA1,
BRCA2, and ATM testing, and 8% voted for large panel testing
including homologous recombination DNA repair (eg,
panels that are also used to assess breast cancer risk).
There was a consensus (92%) that in the presence of a
germline BRCA1, BRCA2, or ATM mutation a prophylactic RP
was not recommended.
The panel was asked whether the presence of a germline
BRCA1, BRCA2, or ATM mutation would influence their
treatment decision in men with low-risk localised prostate
cancer. Forty-five percent voted against active surveillance
in these patients, 35% voted for standard treatment options
(including active surveillance), and 20% voted for another
treatment option.
The panel was asked whether the presence of a germline
BRCA1, BRCA2, or ATM mutation would influence their
treatment decision in men with intermediate- or high-risk
localised prostate cancer. Fifty-two percent of the panel
voted for a RP over RT, 44% of the panel voted for standard
recommendations, and 4% voted for RT over a RP.
9.1. Discussion of germline genetic counselling/testing
The understanding of the role of genetics in prostate cancer
development is evolving rapidly, which is reflected by the
fact that 20% of the panellists recommended genetic
counselling and testing in a majority of men with metastatic
prostate cancer irrespective of family history. Age at
diagnosis itself does not seem to be the best selection
marker, but 74% of the panel who recommended genetic
counselling and testing in selected patients would test in
men aged 60 yr. The impact of a BRCA2 germline mutation
on the management in an otherwise healthy man is not
clear and in the absence of any prospective data there was a
consensus not to recommend prophylactic RP in such men.
Currently, for prostate cancer care providers ordering
germline genetic cancer panel testing or ordering this
testing in the near future, there are several important points
to consider including which genes to test for. There are
emerging prostate cancer practice recommendations onlyof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34or BRCA1, BRCA2, and ATM mutations, yet most next-
eneration sequencing cancer panels include many more
NA repair genes for the same cost. There are currently no
ene-specific data on treatment predication or prostate
ancer risk for most DNA repair genes. Also, when
onsidering genetic testing, appropriate genetic counselling
hould be performed in advance. Germline genetic testing
or the purpose of treatment should be ordered with
dequate pretest and/or posttest genetic counselling. In
articular, there is a need to counsel about the possibility of
 variant of uncertain significance (VUS) being detected
nd/or a pathogenic mutation in a gene in which there are
ot adequate data to alter management for prostate cancer.
atients with VUS should be managed the same as patients
ith a negative test result, and there is a danger that in daily
ractice VUS may be misinterpreted as a positive result. The
uestion of testing of family members is unanswered and
creening recommendations if mutations are detected need
o be generated. There are data suggesting earlier PSA
creening in men with BRCA2 and potentially also in men
ith BRCA1 germline mutations [174]. More data are
eeded to appropriate counsel unaffected male family
embers about prostate cancer risk and make screening
ecommendations.
Large collaborative efforts are underway (eg,
CT00261456, PRACTICAL consortium) to address some
f the open questions. However, in order to move the field
orward more efforts are needed to collaborate—especially
n prostate cancers with germline mutations that occur at a
ow frequency. The panel recommends to be especially
areful (not overinterpret) about treatment recommenda-
ions based on germline mutations in men with localised
rostate cancer.
0. Side effects of systemic treatment: prevention,
anagement, and supportive care
 substantial proportion of men with APC will die of a
oncancer-related cause and must live with the acute and
hronic side effects of treatment. Most men with localised
rostate cancer do not die of their disease, but will spend
he rest of their lives managing the effects of the treatment
hey have undergone. The wishes of our patients and their
amilies are clear: they wish to be cured of their disease or to
ave their survival prolonged, but not necessarily at the cost
f intolerable side effects of treatment. Sometimes it is easy
o lose sight of this goal in the search for better oncological
utcomes.
One-hundred percent of the panel believed that there
as at least moderate evidence that ADT increases the risk
f bone loss and/or fractures; 87% believed this evidence
as strong.
Baseline measurement of vitamin D for men with
rostate cancer starting on ADT was voted for in the
ajority of patients by 43% of the panellists, in a minority of
atients by 26% and 31% of the panellists did not vote for it.
Routine supplementation of calcium and vitamin D for
en with prostate cancer starting on ADT was voted for by
3% of the panel, only of vitamin D by 13%, only calcium byPlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. 2%, and 12% of the panel did not vote for routine
supplementation.
A baseline measurement of bone mineral density in men
with prostate cancer starting on ADT was voted for by 62%
of the panellists in the majority of patients, by 15% only in
patients with nonmetastatic disease and 21% did not vote
for it at all.
Drug therapy to prevent bone loss and/or fractures with
denosumab or a bisphosphonate in the dose and schedule
for osteoporosis prophylaxis in men with prostate cancer
starting on ADT was voted for in the majority of patients by
16% of the panellists, by 70% of panellists only in patients
with documented osteopenia or osteoporosis, and 12% did
not vote for it.
Thirty-five percent of the panellists felt that there is
strong evidence that ADT increases the risk of diabetes, 46%
felt that there is moderate, and 17% that there is weak
evidence for this correlation. Two-percent believe that ADT
does not change the risk of diabetes.
For cardiovascular disease, 12% of the panellists felt that
there is strong evidence that ADT increases the risk, 39% felt
that there is moderate, and 45% that there is weak evidence
for this correlation. Four-percent believe that ADT does not
change the risk of cardiovascular disease.
A history of recent/severe cardiovascular disease influ-
enced the choice of ADT in men with metastatic prostate
cancer for 29% of the panellists in the majority of patients,
for 41% of the panellists for a minority of selected patients,
and for 28% of the panellists it did not influence their choice
of ADT.
For the subset of panellists whose decisions was
influenced by a history of recent/severe cardiovascular
disease, 11% voted for using LHRH agonists, 52% for use of
LHRH antagonists, 6% for orchiectomy, 20% for any form of
intermittent ADT, and 11% voted for bicalutamide 150 mg/d
in such a patient.
Eight-percent of the panellists believed that there is
strong evidence that ADT increases the risk of cognitive
changes and/or dementia, 29% felt that there is moderate,
and 50% that there is weak evidence for this correlation.
Thirteen-percent believe that ADT does not change the risk
of cognitive changes and/or dementia.
For depression, 6% of the panellists believed that there is
strong evidence that ADT increases the risk, 46% felt that
there is moderate, and 44% that there is weak evidence for
this correlation. Four-percent believe that ADT does not
change the risk of depression.
A multidisciplinary management team can include the
necessary expertise to deal with these issues [175]. Improved
outcomes are apparent with involvement of prostate
cancer nurses and care coordinators. Endocrinologists and
andrologists can provide advice on the management of
diabetes, metabolic syndrome, bone health, cardiovascular,
and sexual health. Psychologists can provide support for
the common problems of suicidal risk, distress, and long-
term psychological and sexual morbidity [176–179]. The
exercise physiologist can provide programs to counteract the
effects of ADT, improve psychological symptoms, and
improve overall and disease-specific survival [180–182].t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34The direct provider of care for men with APC can also learn
such skills.
Comprehensive geriatric assessment has been shown to
be associated with a higher probability of completing a
treatment course, fewer modifications of treatment, and
lower toxicity [183,184].
Routine involvement of a multidisciplinary/multiprofes-
sional team for prevention or management of ADT related
adverse effects was voted for by 42% of the panellists for the
majority of patients, by 39% in a minority of selected
patients, and 17% did not vote for it.
Sixty-one percent of the panellists voted for early
access to an expert in symptom palliation or a dedicated
palliative care service and 39% of the panellists did not vote
for it.
There was consensus (94% of the panellists) for access to
opiate pain medication for men with metastatic prostate
cancer and severe pain when lower level pain medication is
not sufficient.
Thirty-percent of the panellists voted for a health status
assessment in men with APC 70 yr before treatment
decision in the majority of patients, 42% voted for it in a
minority of selected patients, and 24% did not vote for it.
The subset of panellists who voted for a health status
assessment voted for comprehensive geriatric assessment
in 26%, G8 and Mini-COG in 29%, G8 alone in 30%, and
another tool in 15%.
There was consensus (98% of the panellists) for regular
physical exercise in men with prostate cancer starting on
ADT.
10.1. Discussion of side effects of systemic treatment:
prevention, management, and supportive care
The aging population of men with APC is now surviving
longer, allowing longer-term complications of treatment to
become apparent and to affect function and symptoms. The
evidence that ADT negatively impacts bone health and the
attendant risk for fractures is considered strong by a
majority of the panel. ADT has also been associated with an
increased risk of metabolic syndrome, type 2 diabetes, and
sarcopenia; however, evidence linking ADT directly as a
cause of vascular disease is weak and there is no convincing
evidence that ADT is linked causally to the development of
dementia as reflected in the vote of the panellists [185–194].
Men should be informed about the acute but also the long-
term side effects of ADT and importantly the possible
preventive measures.
Interestingly, there was no consensus for the routine
assessment of health status in men aged 70 yr, likely based
on the fact that there are no large prospective clinical trials
that have shown that using health status assessment in men
with metastatic prostate cancer has a relevant impact on
outcome, especially when compared with the judgement of
experienced physicians. This recommendation could also
reflect a lack of consensus on what would constitute such a
‘‘health status assessment.’’ Finally, there is a need for
clinical trials and registration studies specifically in this
patient population.Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eu11. Global access to prostate cancer drugs and
treatment in countries with limited resources
The panel voted on a number of questions regarding
treatment options in men with APC in lower and middle-
income countries (LMIC) because the topic of global access
to APC treatments was discussed at APCCC 2017.
If living in a country with limited resources available for
health care, 90% of the panellists voted for orchiectomy as
ADT in the metastatic setting. The remaining 10% voted for
an LHRH agonist.
As second-line endocrine manipulations in LMIC in men
with mCRPC progressing on ADT, 44% of the panellists voted
for a first generation AR antagonist, 24% for steroid
monotherapy, 20% for ketoconazole, 8% for oestrogens,
and 4% for estramustine.
Each of the following drugs is on the World Health
Organization (WHO) essential medicines list and/or they
can be sourced at an affordable price from generic
manufacturer. The panel voted on appropriate treatment
options in the setting of limited health care resources in
men with mCRPC who are progressing on or after docetaxel:
77% of the panellists voted for a platinum, 19% did not vote
for it. Mitoxantrone was voted for by 69% of the panellists.
Thirty-nine percent voted for the use of cyclophosphamide,
53% did not. There was a consensus not to use paclitaxel
(78%) or doxorubicin (84%) in this situation.
11.1. Discussion of global access to prostate cancer drugs and
treatment in countries with limited resources
Prostate cancer generally is more common in higher
income countries, but this is changing as men in LMIC live
longer, due to better control of infectious disease and other
causes of early mortality. Men in LMIC tend to present with
more advanced disease and access to the survival
prolonging agents for mCRPC is limited for many men in
LMIC.
Although the panel recommended orchiectomy as first
choice of ADT in men presenting with metastatic prostate
cancer, the socio-cultural and psychological barriers to such
an intervention must be taken into consideration in such
treatment decisions.
As secondary hormonal treatment option for men with
mCRPC, endocrine manipulations including glucocorticoids,
oestrogens, first generation androgen receptor inhibitors,
and ketoconazole are available and the panel considered
especially first-generation AR inhibitors a valid treatment
option in LMIC.
Abiraterone and enzalutamide are examples of high-cost
drugs with limited access in LMIC. Both drugs were
developed substantially through research in academic
laboratories and cancer centres. In the USA, approved doses
are marketed at US$ 7000/mo, while publicly funded
health systems such as Britain and Canada have been able to
negotiate a substantially lower price of $3000/mo. Generic
abiraterone (but not enzalutamide) is available in India for
about $450/mo, which is, however, still too expensive for
many men with mCRPC in India.of Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
Areas of consensus ( ≥ 75% agreement) APCCC 2017 
Management of high-risk localised and locally advanced prostate cancer 
• undergoing cancer prostate high-risk  cM0 cN0 with men in dissection node Lymph 
prostatectomy: 84% 
Minimal requirement for lymph node sampling in men with cN0 cM0 high-risk prostate cancer 
o Obturator lymph nodes: 98% 
o External iliac lymph nodes: 85% 
o Internal iliac lymph nodes: 90% 
o Not to sample paraaortic lymph nodes: 95% 
For pathology reporting in case of lymphadenectomy: 
o of location and no. and nodes lymph resected of region anatomic and No. 
involved lymph nodes: 94% 
o Micro- vs macrometastases: 81% 
o Metastatic deposits in perinodal fat tissue: 79% 
o Extranodal extension of involved lymph nodes: 81% 
Reporting of prostatectomy specimen in locally advanced prostate cancer: 
o Seminal vesicle involvement: 100% 
o Extent of prostatic involvement: 96% 
o Gleason score or grade group, extraprostatic extension, positive surgical margins: 
no., length, and location, as well as grade at margin: 100% 
o Tertiary Gleason score: 94% 
“Oligometastatic” prostate cancer 
• If tomographytomography–computed emission positron oligometastatic in considered is 
castration-naïve prostate cancer (CNPC) prostate-specific membrane antigen as a tracer: 
76% 
Management of CNPC 
Factors rendering a patient as “not being suitable for docetaxel”: 
o Severe hepatic impairment: 96% 
o Neuropathy grade  ≥2: 82%  
o Platelets <50 × 109/l and/or neutrophils <1.0 × 109/l: 81% 
Docetaxel in addition to androgen deprivation (ADT) therapy in CNPC 
o de novo metastatic CNCP and high-volume disease: 96% 
o Not to add docetaxel in biochemical relapse (N0 M0): 90% 
• 3-weekly docetaxel (75 mg/m2) regimen in CNPC: 96% 
Management of castration-resistant prostate cancer (CRPC) 
First-line CRPC 
o Abiraterone or enzalutamide for asymptomatic men without docetaxel for CNPC: 
86% 
o CNPC: for docetaxel with men asymptomatic for enzalutamide or Abiraterone 
90% 
o Abiraterone or enzalutamide for asymptomatic men with docetaxel for CNPC but  
progressed within ≤6 mo after completion of docetaxel in the CNPC setting: 77% 
o Not to combine radium-223 and docetaxel: 88%  
Second-line CRPC 
o Taxane in men with symptomatic mCRP C who had progressive disease as best 
response to first-line abiraterone or enzalutamide: 96% 
o Taxane in men with symptomatic mCRPC and secondary (acquired) resistance  
or abiraterone first-line of use after progression) by followed response (initial 
enzalutamide: 90% 
o Abiraterone or enzalutamide for asymptomatic men with mCRPC progressing on  
or after docetaxel for mCRPC (without prior abiraterone or enzalutamide): 92% 
o Abiraterone or enzalutamide for symptomatic men with mCRPC progressing on or  
after docetaxel for mCRPC (without prior abiraterone or enzalutamide): 76% 
Fig. 1 – Areas of consensus Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
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Preferred choice between abiraterone and enzalutamide in special situations: 
o Abiraterone in case of a history of falls: 94%  
o Abiraterone in case of baseline significant fatigue: 88%  
o Abiraterone in case of baseline significant neurocognitive impairment: 84%  
o therapy: drug prescription requiring mellitus diabetes of case in Enzalutamide  
84% 
• 3-weekly docetaxel (75 mg/m 2) in the CRPC setting: 86% 
Imaging 
• and bone scintigraphy Computed tomography  for staging and treatment monitoring in 
men with mCRPC on treatment with radium-223: 75% 
Osteoclast-targeted therapies 
• Discontinuation of osteoclast targeted treatment in men who develop osteonecrosis of the 
jaw while on osteoclast-targeted therapy for skeletal related events/symptomatic skeletal 
events prevention: 84% 
Molecular characterisation 
Tumour biopsy reporting in mCRPC 
o BRCA1, BRCA2, and ATM status: 78% 
Liquid biomarkers in routine clinical practice 
o Not to do androgen receptor (AR)-variant 7 testing: 96%  
o Not to do cell-free DNA AR amplification and AR mutation: 92%  
Genetic counselling/testing 
• Not to do a prophylactic prostatectomy in t he presence of a germline BRCA1, BRCA2, or 
ATM mutation: 92% 
Side effects of systemic treatment and supportive care 
• and/or loss bone of risk increases ADT that evidence  strong about patients Advise 
fractures: 87% 
• Regular physical exercise in men with  prostate cancer starting on ADT: 98% 
• Access  to   opiate  pain  medication   for  men  with  metastatic  prostate   cancer  and   sever e 
pain when their  lower  level  pain  medi cation  is  not s uff icien t: 94%   
Global  acc ess t o prost ate can cer  drugs and trea tment in countries wi th li mited r esourc es 
•  Orchiec tomy  as  ADT in the  me tas tatic  sett ing:  90% 
In men  wi th mCRPC who are  progressing  on  or  after  doce taxel : 
o  Platinum  (carbopla tin /cispla tin): 77 % 
o Not pa cli taxel: 78%   
o Not doxoru bicin: 84 % 
Fig. 1. (Continued ).
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EURURO 7424 1–34The following drugs which have shown some antitumour
activity but no OS benefit in men with mCRPC and are on the
WHO essentials medicine list: carboplatin, paclitaxel,
doxorubicin, and cyclophosphamide. Carboplatin was
recommended by a majority of the panellists. Mitoxantrone
is not on the WHO essentials medicine list but has shown a
pain palliation benefit and could be sourced at a reasonable
price. Many of these drugs are substantially cheaper than
the approved and survival prolonging agents for mCRPC and
they can be used sometimes as substitutes for newer agents
in LMIC. While this is a reasonable strategy, it falls far short
of the ideal of providing the most effective treatments to all
men with APC.Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. EuA major goal of this consensus conference is to improve
the management and outcomes of men with APC. However,
it is a suboptimal clinical achievement to show that new
treatments can improve the duration and quality of survival
of men with APC, but to have such treatments unavailable to
a large segment of the global population of men with APC.
The availability of RT as a very effective bone pain palliation
therapy is not given in many countries. We cannot easily
change the way that drugs are developed and marketed for
profit by academic, pharmaceutical, and biotechnology
companies, and we certainly respect and collaborate within
this system for the development of needed new treatments
for men with APC. But men with APC are still unable toof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
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EURURO 7424 1–34ccess optimal treatments, oftentimes not because they
ould not be made available, but because they are not made
vailable at an affordable price. Hence, we encourage
ngoing multidisciplinary and stakeholder dialogue to
urther address this global issue.
2. Conclusions
n the absence of Level I evidence and in areas where there
re conflicting data or conflicting interpretation of available
ata, weighted panellist opinions can be helpful for
reatment decisions in daily routine clinical practice. It is
mportant to note that panellist opinion is not equivalent to
igh-level evidence and that current panellist consensus
ay be disproven by future clinical research.
There were several notable areas of consensus in APCC
017 as summarised in Figure 1.
There were also several notable areas of panellist
isagreement including but not limited to: (1) chemo-
ormonal therapy in ‘‘low-volume’’ CNPC, (2) treatment of
he primary tumour in metastatic disease, (3) radium-223
ombination strategies, (4) use of platinum in mCRPC, (5)
efinition of aggressive variant prostate cancer, (6) use,
chedule, and duration of osteoclast-targeted therapies
specially in the context of newer survival prolonging
CRPC therapies; (7) use of next-generation imaging; (8)
ow to advise men with known BRCA2, BRCA1, or ATM
utations; (9) adjuvant RT; (10) when to initiate SRT; (11)
efinition and treatment for oligometastatic synchronous
nd metachronous prostate cancer; (12) health status
ssessment in patients aged 70 yr; and (13) pathology
eporting of men undergoing a mCRPC biopsy.
The panel members recognise that the voting results may
ontribute to the adoption of unproven or controversial
nterventions and interfere with prospective clinical re-
earch to evaluate the efficacy and safety of those inter-
entions. A problem arising from the widespread initiation
f unvalidated techniques and treatments is that they
chieve a clinical momentum, which makes it very difficult
o conduct effective comparative studies. The panel strongly
ecommends participation in clinical research to inform
linical management with high-level evidence. Important
esearch areas are adjuvant and salvage treatment, diagno-
is, treatment of oligometastatic disease, molecular charac-
erisation, personalised therapy strategies, and supportive
are including the impact of geriatric assessment and
pecific interventions.
We urgently need public and/or charity funding to carry
ut studies in areas such as surgery, RT, or imaging where
inancial support from industry is commonly not available.
Additional relevant questions remain that we were not
ble to address in detail in this meeting such as costs and
ost-effectiveness of drugs, health economic issues, and
atient-reported outcomes. APCCC 2019 plans to address
hese questions and the above-mentioned areas of contro-
ersy and new emerging topics.
uthor contributions: Silke Gillessen had full access to all the data in the
tudy and takes responsibility for the integrity of the data and the
ccuracy of the data analysis.Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. Study concept and design: All authors.
Acquisition of data: All authors.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All
authors.
Statistical analysis: None.
Obtaining funding: Gillessen, Omlin.
Administrative, technical, or material support: None.
Supervision: All authors.
Other: None.
Financial disclosures: Silke Gillessen certiﬁes that all conﬂicts of interest,
including speciﬁc ﬁnancial interests and relationships and afﬁliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/afﬁliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents ﬁled,
received, or pending), are the following: None.
Funding/Support and role of the sponsor: None.
Acknowledgments: We gratefully acknowledge all the participants in the
Advanced Prostate Cancer Consensus Conference (APCCC) for their lively,
stimulating discussions. We thank Thomas Cerny for his support.
We gratefully acknowledge the ﬁnancial support of the following
nonproﬁt organisations for the APCCC 2017: City and Canton of St.
Gallen, Swiss Cancer Research Organisation, European School of
Oncology, Swiss Cancer League, the Swiss Oncology Research Network
SAKK, Swiss Cancer Foundation, Prostate Cancer Foundation. We would
like to thank especially the Movember Foundation for generously
supporting the APCCC 2017 project.
IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).
We would also like to thank the following supporters: Cantonal Hospital
St. Gallen, EMPA Materials Science and Technology, Appenzeller Bier,
Egger Gemu¨sebau, Moving, Schwyter, Swiss, Wernli.
We also acknowledge sponsorship from several different for-proﬁt
organisations including: Astellas, Bayer Health Care, Janssen, Sanoﬁ
Genzyme, Amgen, Bristol-Myers Squibb, Ferring, Roche, Tolmar,
AstraZeneca, Clovis, Medivation, Orion, and Uro-Today (details on the
www.apccc.org). These for-proﬁt organisations supported the confer-
ence ﬁnancially but had no input in the scientiﬁc content or the ﬁnal
publication.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2017.06.002.
References Q2
[1] Gillessen S, Omlin A, Attard G, et al. Management of patients with
advanced prostate cancer: recommendations of the St Gallen
Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol 2015;26:1589–604.
[2] Diamond IR, Grant RC, Feldman BM, et al. Deﬁning consensus: a
systematic review recommends methodologic criteria for report-
ing of Delphi studies. J Clin Epidemiol 2014;67:401–9.
[3] James ND, Spears MR, Clarke NW, et al. Failure-free survival and
radiotherapy in patients with newly diagnosed nonmetastatic
prostate cancer: data from patients in the control arm of the
STAMPEDE trial. JAMA Oncol 2016;2:348–57.
[4] Tombal B, Alcaraz A, James N, Valdagni R, Irani J. Can we improve
the deﬁnition of high-risk, hormone naive, non-metastatic pros-
tate cancer? BJU Int 2014;113:189–99.t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
2395 
2396 
2397 
2398 
2399 
2400 
2401 
2402 
2403 
2404 
2405 
2406 
2407 
2408 
2409 
2410 
2411 
2412 
2413 
2414 
2415 
2416 
2417 
2418 
2419 
2420 
2421 
2422 
2423 
2424 
2425 
2426 
2427 
2428 
2429 
2430 
2431 
2432 
2433 
2434 
2435 
2436 
2437 
2438 
2439 
2440 
2441 
2442 
2443 
2444 
2445 
2446 
2447 
2448 
2449 
2450 
2451 
2452 
2453 
2454 
2455 
2456 
2457 
2458 
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 29
EURURO 7424 1–34[5] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines
on Prostate Cancer. Part 1: screening, diagnosis, and local treat-
ment with curative intent. Eur Urol 2017;71:618–29.
[6] Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate
cancer—major changes in the American Joint Committee on
Cancer eighth edition cancer staging manual. CA Cancer J Clin
2017;67:245–53.
[7] Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary
Gleason Grading of Prostatic Carcinoma: an update with discus-
sion on practical issues to implement the 2014 International
Society of Urological Pathology (ISUP) Consensus Conference on
Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol
2017;41:e1–7.
[8] Moch H, Humphrey PA, Ulbright TM. WHO Classiﬁcation of
Tumours of the Urinary System and Male Genital Organs. ed 4.
Lyon, France: IARC; 2016.
[9] Passoni NM, Fajkovic H, Xylinas E, et al. Prognosis of patients with
pelvic lymph node (LN) metastasis after radical prostatectomy:
value of extranodal extension and size of the largest LN metastasis.
BJU Int 2014;114:503–10.
[10] Briganti A, Larcher A, Abdollah F, et al. Updated nomogram pre-
dicting lymph node invasion in patients with prostate cancer
undergoing extended pelvic lymph node dissection: the essential
importance of percentage of positive cores. Eur Urol 2012;61:
480–7.
[11] Dell’Oglio P, Abdollah F, Suardi N, et al. External validation of the
European association of urology recommendations for pelvic
lymph node dissection in patients treated with robot-assisted
radical prostatectomy. J Endourol 2014;28:416–23.
[12] Hinev AI, Anakievski D, Kolev NH, Hadjiev VI. Validation of nomo-
grams predicting lymph node involvement in patients with pros-
tate cancer undergoing extended pelvic lymph node dissection.
Urol Int 2014;92:300–5.
[13] Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA.
NADiA ProsVue prostate-speciﬁc antigen slope, CAPRA-S, and
prostate cancer-speciﬁc survival after radical prostatectomy.
Urology 2014;84:1427–32.
[14] Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy
after radical prostatectomy for high-risk prostate cancer: long-
term results of a randomised controlled trial (EORTC trial 22911).
Lancet 2012;380:2018–27.
[15] Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy
versus wait-and-see after radical prostatectomy: 10-year follow-
up of the ARO 96–02/AUO AP 09/95 Trial. Eur Urol 2014;66:243–50.
[16] Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy
for pathological T3N0M0 prostate cancer signiﬁcantly reduces risk
of metastases and improves survival: long-term followup of a
randomized clinical trial. J Urol 2009;181:956–62.
[17] Roach 3rd M, Thomas K. Overview of randomized controlled
treatment trials for clinically localized prostate cancer: implica-
tions for active surveillance and the United States preventative
task force report on screening? J Natl Cancer Inst Monogr
2012;2012:221–9.
[18] Gandaglia G, Briganti A, Clarke N, et al. Adjuvant and salvage
radiotherapy after radical prostatectomy in prostate cancer
patients. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.
2017.01.039.
[19] Abdollah F, Gandaglia G, Suardi N, et al. More extensive pelvic
lymph node dissection improves survival in patients with node-
positive prostate cancer. Eur Urol 2015;67:212–9.
[20] Briganti A, Wiegel T, Joniau S, et al. Early salvage radiation therapy
does not compromise cancer control in patients with pT3N0
prostate cancer after radical prostatectomy: results of a match-
controlled multi-institutional analysis. Eur Urol 2012;62:472–87.Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eu[21] Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines
on Prostate Cancer. Part II: treatment of relapsing, metastatic, and
castration-resistant prostate cancer. Eur Urol 2017;71:630–42.
[22] National Comprehensive Cancer Network. Prostate Cancer. 2017.
https://www.nccn.org/professionals/physician_gls/f_guidelines.
asp.
[23] Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a
multi-institutional predictive nomogram for salvage radiotherapy
after radical prostatectomy. J Clin Oncol. In press. http://dx.doi.
org/10.1200/JCO.2016.67.9647.
[24] Abugharib A, Jackson WC, Tumati V, et al. Very early salvage
radiotherapy improves distant metastasis-free survival. J Urol
2017;197:662–8.
[25] Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with
or without short-term hormone therapy for rising prostate-
speciﬁc antigen concentration after radical prostatectomy
(GETUG-AFU 16): a randomised, multicentre, open-label phase
3 trial. Lancet Oncol 2016;17:747–56.
[26] Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or
without antiandrogen therapy in recurrent prostate cancer. N Engl
J Med 2017;376:417–28.
[27] Zaffuto E, Gandaglia G, Fossati N, et al. Early postoperative radio-
therapy is associated with worse functional outcomes in patients
with prostate cancer. J Urol 2017;197:669–75.
[28] Shaikh MP, Alite F, Wu MJ, Solanki AA, Harkenrider MM. Adjuvant
radiotherapy versus wait-and-see strategy for pathologic T3 or
margin-positive prostate cancer: a meta-analysis. Am J Clin Oncol.
In press. http://dx.doi.org/10.1097/COC.0000000000000358.
[29] Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with
or without long-term androgen suppression for prostate cancer
with high metastatic risk: 10-year results of an EORTC randomised
study. Lancet Oncol 2010;11:1066–73.
[30] Bolla M, Collette L, Blank L, et al. Long-term results with immedi-
ate androgen suppression and external irradiation in patients with
locally advanced prostate cancer (an EORTC study): a phase III
randomised trial. Lancet 2002;360:103–6.
[31] Roach 3rd M, Bae K, Speight J, et al. Short-term neoadjuvant
androgen deprivation therapy and external-beam radiotherapy
for locally advanced prostate cancer: long-term results of RTOG
8610. J Clin Oncol 2008;26:585–91.
[32] Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen
suppression using goserelin in unfavorable-prognosis carcinoma
of the prostate treated with deﬁnitive radiotherapy: report of
Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol
1997;15:1013–21.
[33] Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with
radiation therapy compared with radiation therapy alone for
locally advanced prostatic carcinoma: a randomized comparative
trial of the Radiation Therapy Oncology Group. Urology 1995;45:
616–23.
[34] Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol
1995;13:8–10.
[35] Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM.
Oligometastatic prostate cancer: deﬁnitions, clinical outcomes,
and treatment considerations. Nat Rev Urol 2017;14:15–25.
[36] Reyes DK, Pienta KJ. The biology and treatment of oligometastatic
cancer. Oncotarget 2015;6:8491–524.
[37] Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of
regional and distant recurrences after curative treatment of pros-
tate cancer: a systematic review of the literature. Eur Urol
2015;67:852–63.
[38] Ploussard G, Almeras C, Briganti A, et al. Management of node only
recurrence after primary local treatment for prostate cancer: a
systematic review of the literature. J Urol 2015;194:983–8.of Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
2523 
2524 
2525 
2526 
2527 
2528 
2529 
2530 
2531 
2532 
2533 
2534 
2535 
2536 
2537 
2538 
2539 
2540 
2541 
2542 
2543 
2544 
2545 
2546 
2547 
2548 
2549 
2550 
2551 
2552 
2553 
2554 
2555 
2556 
2557 
2558 
2559 
2560 
2561 
2562 
2563 
2564 
2565 
2566 
2567 
2568 
2569 
2570 
2571 
2572 
2573 
2574 
2575 
2576 
2577 
2578 
2579 
2580 
2581 
2582 
2583 
2584 
2585 
2586 
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
2644
2645
2646
2647
2648
2649
2650
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X30
EURURO 7424 1–34[39] Leuprolide Study G. Leuprolide versus diethylstilbestrol for meta-
static prostate cancer. N Engl J Med 1984;311:1281–6.
[40] Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a
large active surveillance cohort of patients with prostate cancer. J
Clin Oncol 2015;33:272–7.
[41] Fizazi K, Lesaunier F, Delva R, et al. A phase III trial of docetaxel-
estramustine in high-risk localised prostate cancer: a planned
analysis of response, toxicity and quality of life in the GETUG
12 trial. Eur J Cancer 2012;48:209–17.
[42] Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy
plus docetaxel and estramustine versus androgen deprivation
therapy alone for high-risk localised prostate cancer (GETUG 12):
a phase 3 randomised controlled trial. Lancet Oncol 2015;16:
787–94.
[43] James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel,
zoledronic acid, or both to ﬁrst-line long-term hormone therapy in
prostate cancer (STAMPEDE): survival results from an adaptive,
multiarm, multistage, platform randomised controlled trial.
Lancet 2016;387:1163–77.
[44] Vale CL, Burdett S, Rydzewska LH, et al. Addition of docetaxel or
bisphosphonates to standard of care in men with localised or
metastatic, hormone-sensitive prostate cancer: a systematic re-
view and meta-analyses of aggregate data. Lancet Oncol
2016;17:243–56.
[45] Maximum androgen blockade in advanced prostate cancer: an
overview of the randomised trials. Prostate Cancer Trialists’ Col-
laborative Group. Lancet 2000;355:1491–8.
[46] James ND, Spears MR, Clarke NW, et al. Survival with newly
diagnosed metastatic prostate cancer in the ‘‘docetaxel era’’: data
from 917 patients in the control arm of the STAMPEDE Trial (MRC
PR08, CRUK/06/019). Eur Urol 2015;67:1028–38.
[47] Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone
or with docetaxel in non-castrate metastatic prostate cancer
(GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet
Oncol 2013;14:149–58.
[48] Gravis G, Boher JM, Fizazi K, et al. Prognostic factors for survival in
noncastrate metastatic prostate cancer: validation of the glass
model and development of a novel simpliﬁed prognostic model.
Eur Urol 2015;68:196–204.
[49] Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy
in metastatic hormone-sensitive prostate cancer. N Engl J Med
2015;373:737–46.
[50] Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy
(ADT) plus docetaxel versus ADT alone in metastatic non castrate
prostate cancer: impact of metastatic burden and long-term sur-
vival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur
Urol 2016;70:256–62.
[51] Kawano M, Mabuchi S, Matsumoto Y, et al. The signiﬁcance of
G-CSF expression and myeloid-derived suppressor cells in the
chemoresistance of uterine cervical cancer. Sci Rep 2015;5:18217.
[52] Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF
facilitates neoplastic growth through a granulocytic myeloid-
derived suppressor cell-dependent mechanism. PloS One 2011;
6:e27690.
[53] Welte T, Kim IS, Tian L, et al. Oncogenic mTOR signalling recruits
myeloid-derived suppressor cells to promote tumour initiation.
Nat Cell Biol 2016;18:632–44.
[54] Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in
patients with de novo metastatic prostate cancer: morbidity, man-
agement, and disease outcome. Urol Oncol 2015;33:202 e9–17.
[55] Won AC, Gurney H, Marx G, De Souza P, Patel MI. Primary
treatment of the prostate improves local palliation in men who
ultimately develop castrate-resistant prostate cancer. BJU Int
2013;112:E250–5.Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. [56] Culp SH, Schellhammer PF, Williams MB. Might men diagnosed
with metastatic prostate cancer beneﬁt from deﬁnitive treatment
of the primary tumor? A SEER-based study. Eur Urol 2014;65:
1058–66.
[57] Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with
prostate radiation in addition to androgen deprivation therapy for
men with newly diagnosed metastatic prostate cancer. J Clin
Oncol 2016;34:2835–42.
[58] Loppenberg B, Dalela D, Karabon P, et al. The Impact of local
treatment on overall survival in patients with metastatic prostate
cancer on diagnosis: a national cancer data base analysis. Eur Urol.
In press. http://dx.doi.org/10.1016/j.eururo.2016.04.031.
[59] Engel J, Bastian PJ, Baur H, et al. Survival beneﬁt of radical
prostatectomy in lymph node-positive patients with prostate
cancer. Eur Urol 2010;57:754–61.
[60] Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with
or without radiation therapy for clinically node-positive prostate
cancer. J Natl Cancer Inst 2015;107.
[61] Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor
signaling regulates DNA repair in prostate cancers. Cancer Discov
2013;3:1245–53.
[62] Komura K, Jeong SH, Hinohara K, et al. Resistance to docetaxel in
prostate cancer is associated with androgen receptor activation
and loss of KDM5D expression. Proc Natl Acad Sci U S A
2016;113:6259–64.
[63] Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and
outcome in early-stage breast cancer: results of a prospective
cohort study. J Clin Oncol 2002;20:42–51.
[64] Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus
no treatment of the primary tumour in metastatic breast cancer:
an open-label randomised controlled trial. Lancet Oncol 2015;16:
1380–8.
[65] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunother-
apy for castration-resistant prostate cancer. N Engl J Med 2010;
363:411–22.
[66] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic
prostate cancer without previous chemotherapy. N Engl J Med
2013;368:138–48.
[67] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in
metastatic prostate cancer before chemotherapy. N Engl J Med
2014;371:424–33.
[68] Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N
Engl J Med 2004;351:1502–12.
[69] Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estra-
mustine compared with mitoxantrone and prednisone for advanced
refractory prostate cancer. N Engl J Med 2004;351:1513–20.
[70] Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223
and survival in metastatic prostate cancer. N Engl J Med 2013;369:
213–23.
[71] de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and in-
creased survival in metastatic prostate cancer. N Engl J Med
2011;364:1995–2005.
[72] de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus caba-
zitaxel or mitoxantrone for metastatic castration-resistant pros-
tate cancer progressing after docetaxel treatment: a randomised
open-label trial. Lancet 2010;376:1147–54.
[73] Scher HI, Fizazi K, Saad F, et al. Increased survival with enzaluta-
mide in prostate cancer after chemotherapy. N Engl J Med
2012;367:1187–97.
[74] Hager S, Ackermann CJ, Joerger M, Gillessen S, Omlin A. Anti-
tumour activity of platinum compounds in advanced prostate
cancer-a systematic literature review. Ann Oncol 2016;27:
975–84.t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
2651 
2652 
2653 
2654 
2655 
2656 
2657 
2658 
2659 
2660 
2661 
2662 
2663 
2664 
2665 
2666 
2667 
2668 
2669 
2670 
2671 
2672 
2673 
2674 
2675 
2676 
2677 
2678 
2679 
2680 
2681 
2682 
2683 
2684 
2685 
2686 
2687 
2688 
2689 
2690 
2691 
2692 
2693 
2694 
2695 
2696 
2697 
2698 
2699 
2700 
2701 
2702 
2703 
2704 
2705 
2706 
2707 
2708 
2709 
2710 
2711 
2712 
2713 
2714 
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2736
2737
2738
2739
2740
2741
2742
2743
2744
2745
2746
2747
2748
2749
2750
2751
2752
2753
2754
2755
2756
2757
2758
2759
2760
2761
2762
2763
2764
2765
2766
2767
2768
2769
2770
2771
2772
2773
2774
2775
2776
2777
2778
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 31
EURURO 7424 1–34[75] Lorente D, Mateo J, Zafeiriou Z, et al. Switching and withdrawing
hormonal agents for castration-resistant prostate cancer. Nat Rev
Urol 2015;12:37–47.
[76] Lorente D, Omlin A, Ferraldeschi R, et al. Tumour responses
following a steroid switch from prednisone to dexamethasone
in castration-resistant prostate cancer patients progressing on
abiraterone. Br J Cancer 2014;111:2248–53.
[77] Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al.
2-Weekly versus 3-weekly docetaxel to treat castration-resistant
advanced prostate cancer: a randomised, phase 3 trial. Lancet
Oncol 2013;14:117–24.
[78] Pezaro CJ, Omlin A, Lorente D, et al. Visceral disease in castration-
resistant prostate cancer. Eur Urol 2014;65:270–3.
[79] Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of
castration-resistant prostate cancer. Clin Cancer Res 2014;20:
2846–50.
[80] Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of
resistance to androgen receptor inhibitors in prostate cancer.
Nat Rev Cancer 2015;15:701–11.
[81] Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based che-
motherapy for variant castrate-resistant prostate cancer. Clin
Cancer Res 2013;19:3621–30.
[82] Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis
of alkaline phosphatase, lactate dehydrogenase, and prostate-
speciﬁc antigen dynamics in the phase 3 ALSYMPCA trial with
radium-223. Ann Oncol 2017;28:1090–7.
[83] Keizman D, Fosboel MO, Reichegger H, et al. Imaging response
during therapy with radium-223 for castration-resistant prostate
cancer with bone metastases-analysis of an international multi-
center database. Prostate Cancer Prostatic Dis. In press. http://dx.
doi.org/10.1038/pcan.2017.6.
[84] Basler L, Kroeze SG, Guckenberger M. SBRT for oligoprogressive
oncogene addicted NSCLC. Lung Cancer 2017;106:50–7.
[85] Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic
classiﬁcation of prostate cancer with neuroendocrine differentia-
tion. Am J Surg Pathol 2014;38:756–67.
[86] Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis Reporting
and Data System for Prostate Cancer: practical guidelines for
acquisition, interpretation, and reporting of whole-body magnetic
resonance imaging-based evaluations of multiorgan involvement
in advanced prostate cancer. Eur Urol 2017;71:81–92.
[87] Gillessen S, Fanti S, Omlin A. Reply to the letter to the editor
‘management of patients with advanced prostate cancer: recom-
mendations of the St Gallen Advanced Prostate Cancer Consensus
Conference (APCCC) 2015’ by Gillessen et al. Ann Oncol 2015;
26:2354–5.
[88] Bjurlin MA, Rosenkrantz AB, Beltran LS, Raad RA, Taneja SS.
Imaging and evaluation of patients with high-risk prostate cancer.
Nat Rev Urol 2015;12:617–28.
[89] Rozet F, Roumeguere T, Spahn M, Beyersdorff D, Hammerer P.
Non-metastatic castrate-resistant prostate cancer: a call for im-
proved guidance on clinical management. World J Urol 2016;34:
1505–13.
[90] Hovels AM, Heesakkers RA, Adang EM, et al. The diagnostic
accuracy of CT and MRI in the staging of pelvic lymph nodes in
patients with prostate cancer: a meta-analysis. Clin Radiol 2008;
63:387–95.
[91] Lecouvet FE, El Mouedden J, Collette L, et al. Can whole-body
magnetic resonance imaging with diffusion-weighted imaging
replace Tc 99m bone scanning and computed tomography for
single-step detection of metastases in patients with high-risk
prostate cancer? Eur Urol 2012;62:68–75.
[92] Jambor I, Kuisma A, Ramadan S, et al. Prospective evaluation of
planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT andPlease cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Euwhole body 1.5T MRI, including DWI, for the detection of bone
metastases in high risk breast and prostate cancer patients:
SKELETA clinical trial. Acta Oncol 2016;55:59–67.
[93] Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI,
SPECT, and bone scintigraphy in the diagnosis of bone metastases
in patients with prostate cancer: a meta-analysis. Skeletal Radiol
2014;43:1503–13.
[94] Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of
magnetic resonance imaging for the detection of bone metastasis
in prostate cancer: a systematic review and meta-analysis. Eur
Urol. http://dx.doi.org/10.1016/j.eururo.2017.03.042.
[95] Minamimoto R, Loening A, Jamali M, et al. Prospective comparison
of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG
PET/CT, and whole-body MRI in patients with breast and prostate
cancer. J Nucl Med 2015;56:1862–8.
[96] Schwenck J, Rempp H, Reischl G, et al. Comparison of 68Ga-
labelled PSMA-11 and 11C-choline in the detection of prostate
cancer metastases by PET/CT. Eur J Nucl Med Mol Imaging
2017;44:92–101.
[97] Bach-Gansmo T, Nanni C, Nieh PT, et al. Multisite experience of the
safety, detection rate and diagnostic performance of ﬂuciclovine
(18F) positron emission tomography/computerized tomography
imaging in the staging of biochemically recurrent prostate cancer.
J Urol 2017;197:676–83.
[98] Nanni C, Zanoni L, Pultrone C, et al. (18)F-FACBC (anti1-amino-3-
(18)F-ﬂuorocyclobutane-1-carboxylic acid) versus (11)C-choline
PET/CT in prostate cancer relapse: results of a prospective trial. Eur
J Nucl Med Mol Imaging 2016;43:1601–10.
[99] Yu EY, Miller K, Nelson J, et al. Detection of previously unidentiﬁed
metastatic disease as a leading cause of screening failure in a
phase III trial of zibotentan versus placebo in patients with non-
metastatic, castration resistant prostate cancer. J Urolo 2012;188:
103–9.
[100] Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and
biochemical relapse of prostate cancer: a systematic review and
meta-analysis. Clin Nucl Med 2013;38:305–14.
[101] Colombie M, Campion L, Bailly C, et al. Prognostic value of meta-
bolic parameters and clinical impact of (1)(8)F-ﬂuorocholine PET/
CT in biochemical recurrent prostate cancer. Eur J Nucl Med Mol
Imaging 2015;42:1784–93.
[102] Giovacchini G, Incerti E, Mapelli P, et al. [(1)(1)C]Choline PET/CT
predicts survival in hormone-naive prostate cancer patients with
biochemical failure after radical prostatectomy. Eur J Nucl Med
Mol Imaging 2015;42:877–84.
[103] Pﬁster D, Porres D, Heidenreich A, et al. Detection of recurrent
prostate cancer lesions before salvage lymphadenectomy is more
accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluor-
oethylcholine PET/CT. Eur J Nucl Med Mol Imaging 2016;43:
1410–7.
[104] Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective compari-
son of 18F-ﬂuoromethylcholine versus 68Ga-PSMA PET/CT in
prostate cancer patients who have rising PSA After curative treat-
ment and are being considered for targeted therapy. J Nucl Med
2015;56:1185–90.
[105] Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of
PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in
the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol
Imaging 2015;42:197–209.
[106] Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid
(6)(8)Ga-PSMA Ligand PET/CT in 248 patients with biochemical
recurrence after radical prostatectomy. J Nucl Med 2015;56:
668–74.
[107] Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives
for castration-resistant prostate cancer: updated recommendationsof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
2779 
2780 
2781 [
2782 
2783 
2784 
2785 [
2786 
2787 
2788 
2789 [
2790 
2791 
2792 
2793 [
2794 
2795 
2796 [
2797 
2798 
2799 [
2800 
2801 
2802 [
2803 
2804 
2805 [
2806 
2807 
2808 
2809 [
2810 
2811 
2812 [
2813 
2814 [
2815 
2816 
2817 
2818 [
2819 
2820 
2821 
2822 [
2823 
2824 
2825 
2826 [
2827 
2828 
2829 
2830 [
2831 
2832 
2833 [
2834 
2835 
2836 
2837 [
2838 
2839 
2840 
2841 [
2842 
2843
2844
2845
2846
2847
2848
2849
2850
2851
2852
2853
2854
2855
2856
2857
2858
2859
2860
2861
2862
2863
2864
2865
2866
2867
2868
2869
2870
2871
2872
2873
2874
2875
2876
2877
2878
2879
2880
2881
2882
2883
2884
2885
2886
2887
2888
2889
2890
2891
2892
2893
2894
2895
2896
2897
2898
2899
2900
2901
2902
2903
2904
2905
2906
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X32
EURURO 7424 1–34from the Prostate Cancer Clinical Trials Working Group 3. J Clin
Oncol 2016;34:1402–18.
108] Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free
survival as a response biomarker in metastatic castration-
resistant prostate cancer: COU-AA-302 results. J Clin Oncol
2015;33:1356–63.
109] Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression
with nonrising PSA in metastatic castration-resistant prostate
cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic
Dis 2017;20:221–7.
110] Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive mea-
surement of androgen receptor signaling with a positron-emitting
radiopharmaceutical that targets prostate-speciﬁc membrane an-
tigen. Proc Natl Acad Sci U S A 2011;108:9578–82.
111] Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene
KL. Targeted PET imaging for prostate-speciﬁc membrane antigen
in prostate cancer. Future Oncol 2016;12:2393–6.
112] Hope TA, Truillet C, Ehman EC, et al. 68Ga-PSMA-11 PET imaging
of response to androgen receptor inhibition: ﬁrst human experi-
ence. J Nucl Med 2017;58:81–4.
113] Wright Jr GL, Grob BM, Haley C, et al. Upregulation of prostate-
speciﬁc membrane antigen after androgen-deprivation therapy.
Urology 1996;48:326–34.
114] Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in
circulating tumor cells as a marker of hormonally responsive
prostate cancer. Cancer Discov 2012;2:995–1003.
115] Meller B, Bremmer F, Sahlmann CO, et al. Alterations in androgen
deprivation enhanced prostate-speciﬁc membrane antigen
(PSMA) expression in prostate cancer cells as a target for diag-
nostics and therapy. EJNMMI Res 2015;5:66.
116] Rowe SP, Deville C, Paller C, et al. Uptake of 18F-DCFPyL in Paget’s
disease of bone, an important potential pitfall in clinical interpre-
tation of PSMA PET studies. Tomography 2015;1:81–4.
117] Hofman MS, Iravani A. Gallium-68 prostate-speciﬁc membrane
antigen PET imaging. PET Clin 2017;12:219–34.
118] De Giorgi U, Caroli P, Scarpi E, et al. (18)F-Fluorocholine PET/CT for
early response assessment in patients with metastatic castration-
resistant prostate cancer treated with enzalutamide. Eur J Nucl
Med Mol Imaging 2015;42:1276–83.
119] Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemo-
therapy and PET-guided radiotherapy in patients with advanced
stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-
label, phase 3 non-inferiority trial. Lancet 2012;379:1791–9.
120] Perez-Lopez R, Mateo J, Mossop H, et al. Diffusion-weighted
imaging as a treatment response biomarker for evaluating bone
metastases in prostate cancer: a pilot study. Radiology 2017;283:
168–77.
121] Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic
acid for treatment of bone metastases in men with castration-
resistant prostate cancer: a randomised, double-blind study.
Lancet 2011;377:813–22.
122] Saad F. Zoledronic acid signiﬁcantly reduces pathologic fractures
in patients with advanced-stage prostate cancer metastatic to
bone. Clin Prostate Cancer 2002;1:145–52.
123] Saad F, Gleason DM, Murray R, et al. Long-term efﬁcacy of zole-
dronic acid for the prevention of skeletal complications in patients
with metastatic hormone-refractory prostate cancer. J Natl Cancer
Inst 2004;96:879–82.
124] Smith MR, Saad F, Coleman R, et al. Denosumab and bone-
metastasis-free survival in men with castration-resistant prostate
cancer: results of a phase 3, randomised, placebo-controlled trial.
Lancet 2012;379:39–46.
125] Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of
early zoledronic acid in men with castration-sensitive prostatePlease cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. cancer and bone metastases: results of CALGB 90202 (alliance). J
Clin Oncol 2014;32:1143–50.
[126] James ND, Pirrie SJ, Pope AM, et al. Clinical outcomes and survival
following treatment of metastatic castrate-refractory prostate
cancer with docetaxel alone or with strontium-89, zoledronic
acid, or both: The TRAPEZE randomized clinical trial. JAMA Oncol
2016;2:493–9.
[127] Smith MR, Coleman RE, Klotz L, et al. Denosumab for the preven-
tion of skeletal complications in metastatic castration-resistant
prostate cancer: comparison of skeletal-related events and symp-
tomatic skeletal events. Ann Oncol 2015;26:368–74.
[128] Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride
on symptomatic skeletal events in patients with castration-resis-
tant prostate cancer and bone metastases: results from a phase 3,
double-blind, randomised trial. Lancet Oncol 2014;15:738–46.
[129] Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-
interval vs standard dosing of zoledronic acid on skeletal events in
patients with bone metastases: a randomized clinical trial. JAMA
2017;317:48–58.
[130] Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer
therapies and jaw necrosis. Br Dent J 2015;219:203–7.
[131] Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and
outcomes of osteonecrosis of the jaw: integrated analysis from
three blinded active-controlled phase III trials in cancer patients
with bone metastases. Ann Oncol 2012;23:1341–7.
[132] Beltran H, Prandi D, Mosquera JM, et al. Divergent clonal evolution
of castration-resistant neuroendocrine prostate cancer. Nat Med
2016;22:298–305.
[133] Beltran H, Eng K, Mosquera JM, et al. Whole-exome sequencing of
metastatic cancer and biomarkers of treatment response. JAMA
Oncol 2015;1:466–74.
[134] Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor
defects characterize clinically deﬁned aggressive variant prostate
cancers. Clin Cancer Res 2016;22:1520–30.
[135] Dardenne E, Beltran H, Benelli M, et al. N-Myc Induces an EZH2-
mediated transcriptional program driving neuroendocrine pros-
tate cancer. Cancer Cell 2016;30:563–77.
[136] Bishop JL, Thaper D, Vahid S, et al. The master neural transcription
factor BRN2 is an androgen receptor-suppressed driver of neuro-
endocrine differentiation in prostate cancer. Cancer Discov
2017;7:54–71.
[137] Li Y, Donmez N, Sahinalp C, et al. SRRM4 drives neuroendocrine
transdifferentiation of prostate adenocarcinoma under androgen
receptor pathway inhibition. Eur Urol 2017;71:68–78.
[138] Mu P, Zhang Z, Benelli M, et al. SOX2 promotes lineage plasticity
and antiandrogen resistance in TP53- and RB1-deﬁcient prostate
cancer. Science 2017;355:84–8.
[139] Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical
genomics of advanced prostate cancer. Cell 2015;161:1215–28.
[140] Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and
olaparib in metastatic prostate cancer. N Engl J Med 2015;373:
1697–708.
[141] Ku SY, Rosario S, Wang Y, et al. Rb1 and Trp53 cooperate to
suppress prostate cancer lineage plasticity, metastasis, and anti-
androgen resistance. Science 2017;355:78–83.
[142] Pritchard CC, Morrissey C, Kumar A, et al. Complex MSH2 and
MSH6 mutations in hypermutated microsatellite unstable ad-
vanced prostate cancer. Nat Commun 2014;5:4988.
[143] Wyatt AW, Azad AA, Volik SV, et al. Genomic Alterations in cell-
free dna and enzalutamide resistance in castration-resistant pros-
tate cancer. JAMA Oncol 2016;2:1598–606.
[144] Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to
enzalutamide and abiraterone in prostate cancer. N Engl J Med
2014;371:1028–38.t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
2907 
2908 
2909 
2910 
2911 
2912 
2913 
2914 
2915 
2916 
2917 
2918 
2919 
2920 
2921 
2922 
2923 
2924 
2925 
2926 
2927 
2928 
2929 
2930 
2931 
2932 
2933 
2934 
2935 
2936 
2937 
2938 
2939 
2940 
2941 
2942 
2943 
2944 
2945 
2946 
2947 
2948 
2949 
2950 
2951 
2952 
2953 
2954 
2955 
2956 
2957 
2958 
2959 
2960 
2961 
2962 
2963 
2964 
2965 
2966 
2967 
2968 
2969 
2970
2971
2972
2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019
3020
3021
3022
3023
3024
3025
3026
3027
3028
3029
3030
3031
3032
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X 33
EURURO 7424 1–34[145] Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and
prostate-speciﬁc antigen RNA levels in blood with efﬁcacy of
abiraterone acetate and enzalutamide treatment in men with
prostate cancer. Clin Cancer Res 2017;23:726–34.
[146] Del Re M, Biasco E, Crucitta S, et al. The detection of androgen
receptor splice variant 7 in plasma-derived exosomal RNA strong-
ly predicts resistance to hormonal therapy in metastatic prostate
cancer patients. Eur Urol 2017;71:680–7.
[147] Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on
circulating tumor cells as a treatment-speciﬁc biomarker with
outcomes and survival in castration-resistant prostate cancer.
JAMA Oncol 2016;2:1441–9.
[148] Romanel A, Gasi Tandefelt D, Conteduca V, et al. Plasma AR and
abiraterone-resistant prostate cancer. Sci Transl Med 2015;7:
312re10.
[149] Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape
of lethal castration-resistant prostate cancer. Nature 2012;487:
239–43.
[150] Mateo J, Boysen G, Barbieri CE, et al. DNA repair in prostate cancer:
biology and clinical implications. Eur Urol 2017;71:417–25.
[151] Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.
Biallelic inactivation of BRCA2 in platinum-sensitive metastatic
castration-resistant prostate cancer. Eur Urol 2016;69:992–5.
[152] Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-
blind, phase III study of prednisone and either satraplatin or
placebo in patients with castrate-refractory prostate cancer pro-
gressing after prior chemotherapy: the SPARC trial. J Clin Oncol
2009;27:5431–8.
[153] Nghiem B, Zhanga X, Lama H-M, et al. Mismatch repair enzyme
expression in primary and castrate resistant prostate cancer
Asian. J Urol 2016;3:223–8.
[154] Schweizer MT, Cheng HH, Tretiakova MS, et al. Mismatch repair
deﬁciency may be common in ductal adenocarcinoma of the
prostate. Oncotarget 2016;7:82504–10.
[155] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with
mismatch-repair deﬁciency. N Engl J Med 2015;372:2509–20.
[156] Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among
Korean-American immigrants in the United States and native
Koreans in South Korea. Cancer Control 2007;14:78–85.
[157] Mucci LA, Hjelmborg JB, Harris JR, et al. Familial risk and heritability
of cancer among twins in Nordic countries. JAMA 2016;315:68–76.
[158] Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Sys-
tematic population-based assessment of cancer risk in ﬁrst-
degree relatives of cancer probands. J Natl Cancer Inst 1994;86:
1600–8.
[159] Lange EM. Male Reproductive Cancers: Epidemiology, Pathology
and Genetics. New York, NY: Springer; 2010.
[160] Zeigler-Johnson CM, Rennert H, Mittal RD, et al. Evaluation of
prostate cancer characteristics in four populations worldwide.
Canadian J Urol 2008;15:4056–64.
[161] Cui J, Staples MP, Hopper JL, English DR, McCredie MR, Giles GG.
Segregation analyses of 1,476 population-based Australian families
affected by prostate cancer. Am J Hum Genet 2001;68:1207–18.
[162] Ahmed M, Eeles R. Germline genetic proﬁling in prostate cancer:
latest developments and potential clinical applications. Future Sci
OA 2016;2:FSO87.
[163] Thompson D, Easton D, Breast Cancer Linkage C. Variation in
cancer risks, by mutation position, in BRCA2 mutation carriers.
Am J Hum Genet 2001;68:410–9.
[164] Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a
moderate penetrance gene contributing to young-onset prostate
cancer: implications for genetic testing in prostate cancer
patients. Br J Cancer 2011;105:1230–4.Please cite this article in press as: Gillessen S, et al. Management 
Advanced Prostate Cancer Consensus Conference APCCC 2017. Eu[165] Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline
BRCA1 mutations increase prostate cancer risk. Br J Cancer
2012;106:1697–701.
[166] Leongamornlert D, Saunders E, Dadaev T, et al. Frequent germline
deleterious mutations in DNA repair genes in familial prostate
cancer cases are associated with advanced disease. Br J Cancer
2014;110:1663–72.
[167] Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of
prostate cancer in men with a BRCA2 mutation. Br J Cancer
2008;99:371–4.
[168] Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate
cancer progression and survival in BRCA2 mutation carriers. J
Natl Cancer Inst 2007;99:929–35.
[169] Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are
associated with higher risk of nodal involvement, distant metas-
tasis, and poor survival outcomes in prostate cancer. J Clin Oncol
2013;31:1748–57.
[170] Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA muta-
tions on metastatic relapse and cause-speciﬁc survival after
radical treatment for localised prostate cancer. Eur Urol
2015;68:186–93.
[171] Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene
mutations in men with metastatic prostate cancer. N Engl J Med
2016;375:443–53.
[172] Annala M, Struss WJ, Warner EW, et al. Treatment outcomes and
tumor loss of heterozygosity in germline DNA repair-deﬁcient
prostate cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.
eururo.2017.02.023.
[173] Na R, Zheng SL, Han M, et al. Germline mutations in ATM and
BRCA1/2 distinguish risk for lethal and indolent prostate cancer
and are associated with early age at death. Eur Urol 2017;71:
740–7.
[174] Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer
screening in BRCA1 and BRCA2 mutation carriers: results from the
initial screening round of the IMPACT study. Eur Urol 2014;66:
489–99.
[175] Rao K, Manya K, Azad A, et al. Uro-oncology multidisciplinary
meetings at an Australian tertiary referral centre–impact on
clinical decision-making and implications for patient inclusion.
BJU Int 2014;114(Suppl 1):50–4.
[176] Chambers SK, Ferguson M, Gardiner RA, Aitken J, Occhipinti S.
Intervening to improve psychological outcomes for men with
prostate cancer. Psychooncology 2013;22:1025–34.
[177] Chambers SK, Occhipinti S, Foley E, et al. Mindfulness-based
cognitive therapy in advanced prostate cancer: a randomized
controlled trial. J Clin Oncol 2017;35:291–7.
[178] Chambers SK, Occhipinti S, Schover L, et al. A randomised con-
trolled trial of a couples-based sexuality intervention for men
with localised prostate cancer and their female partners. Psy-
chooncology 2015;24:748–56.
[179] Ussher JM, Perz J, Kellett A, et al. Health-related quality of life,
psychological distress, and sexual changes following prostate
cancer: a comparison of gay and bisexual men with heterosexual
men. J Sex Med 2016;13:425–34.
[180] Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE,
Courneya KS. Physical activity and survival after prostate cancer.
Eur Urol 2016;70:576–85.
[181] Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and
reduction of treatment side effects in prostate cancer patients.
Med Sci Sports Exerc 2006;38:2045–52.
[182] Galvao DA, Spry N, Denham J, et al. A multicentre year-long
randomised controlled trial of exercise training targeting physical
functioning in men with prostate cancer previously treated withof Patients with Advanced Prostate Cancer: The Report of the
r Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
3033 
3034 
3035 [
3036 
3037 
3038 
3039 [
3040 
3041 
3042 [
3043 
3044 
3045 
3046 [
3047 
3048 
3049 
3050 [
3051 
3052 
3053
3054
3055
3056
3057
3058
3059
3060
3061
3062
3063
3064
3065
3066
3067
3068
3069
3070
3071
3072
3073
E U R O P E A N U R O L O G Y X X X ( 2 0 1 7 ) X X X – X X X34
EURURO 7424 1–34androgen suppression and radiation from TROG 03.04 RADAR. Eur
Urol 2014;65:856–64.
183] Droz JP, Albrand G, Gillessen S, et al. Management of prostate
cancer in elderly patients: recommendations of a Task Force of the
International Society of Geriatric Oncology. Eur Urol. In press.
http://dx.doi.org/10.1016/j.eururo.2016.12.025.
184] Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive
geriatric assessment interventions on tolerance to chemotherapy
in older people. Br J Cancer 2015;112:1435–44.
185] Keating NL, O’Malley A, Freedland SJ, Smith MR. Diabetes and
cardiovascular disease during androgen deprivation therapy:
observational study of veterans with prostate cancer. J Natl Cancer
Inst 2012;104:1518–23.
186] Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and
cardiovascular disease during androgen deprivation therapy:
observational study of veterans with prostate cancer. J Natl Cancer
Inst 2010;102:39–46.
187] Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular
disease during androgen deprivation therapy for prostate cancer.
J Clin Oncol 2006;24:4448–56.Please cite this article in press as: Gillessen S, et al. Managemen
Advanced Prostate Cancer Consensus Conference APCCC 2017. [188] Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen
deprivation therapy on cardiovascular disease and diabetes. J Clin
Oncol 2009;27:3452–8.
[189] Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body
composition during androgen deprivation therapy for prostate
cancer. J Clin Endocrinol Metab 2002;87:599–603.
[190] Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined
androgen blockade for prostate cancer. J Clin Endocrinol Metab
2006;91:1305–8.
[191] Nead KT, Gaskin G, Chester C, et al. Androgen deprivation therapy
and future Alzheimer’s disease risk. J Clin Oncol 2016;34:566–71.
[192] Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah
NH. Association between androgen deprivation therapy and risk
of dementia. JAMA Oncol 2017;3:49–55.
[193] Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen
deprivation therapy and the risk of dementia in patients with
prostate cancer. J Clin Oncol 2017;35:201–7.
[194] Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-
deprivation therapy on cognitive function in men with nonmeta-
static prostate cancer. J Clin Oncol 2010;28:5030–7.t of Patients with Advanced Prostate Cancer: The Report of the
Eur Urol (2017), http://dx.doi.org/10.1016/j.eururo.2017.06.002
